Document:

Exhibit 4.15

CONFORMED COPY

	
  

 
	

 

 
	
  

 
	
 QUEST DIAGNOSTICS INCORPORATED,

 
	
  

 
	
 as Issuer

 
	
  

 
	
 THE SUBSIDIARY GUARANTORS NAMED HEREIN,

 
	
  

 
	
 as Subsidiary Guarantors

 
	
  

 
	
 and

 
	
  

 
	
 THE BANK OF NEW YORK MELLON,

 
	
  

 
	
 as Trustee

 
	
  

 
	
 Fourteenth Supplemental Indenture

 
	
  

 
	
 Dated as of March 24, 2011

 
	
  

 
	

 

 

TABLE OF CONTENTS

	
  

 	
  

 	
  

 	
  

 	
  

 	
  

 
	
  

 	
  

 	
  

 	
  

 	
  

 	
 Page

 
	
  

 	
  

 	
  

 	
  

 	
  

 	
  

 
	
 ARTICLE I. DEFINITIONS

 	
  

 	
 2

 
	
  

 	
  

 	
  

 	
  

 	
  

 
	
  

 	
 SECTION 1.1.

 	
  

 	
 Certain Terms Defined in
 the Indenture

 	
  

 	
 2

 
	
  

 	
  

 	
  

 	
  

 	
  

 	
  

 
	
  

 	
 SECTION 1.2.

 	
  

 	
 Definitions

 	
  

 	
 2

 
	
  

 	
  

 	
  

 	
  

 	
  

 	
  

 
	
  

 	
 SECTION 1.3.

 	
  

 	
 Other Definitions

 	
  

 	
 5

 
	
  

 	
  

 	
  

 	
  

 	
  

 	
  

 
	
 ARTICLE II. FORM AND TERMS
 OF THE NOTES

 	
  

 	
 5

 
	
  

 	
  

 	
  

 
	
  

 	
 SECTION 2.1.

 	
  

 	
 Form and Dating

 	
  

 	
 5

 
	
  

 	
  

 	
  

 	
  

 	
  

 	
  

 
	
  

 	
 SECTION 2.2.

 	
  

 	
 Terms of the Notes

 	
  

 	
 7

 
	
  

 	
  

 	
  

 	
  

 	
  

 	
  

 
	
  

 	
 SECTION 2.3.

 	
  

 	
 [RESERVED]

 	
  

 	
 12

 
	
  

 	
  

 	
  

 	
  

 	
  

 	
  

 
	
  

 	
 SECTION 2.4.

 	
  

 	
 Application of the Article
 of the Indenture Regarding Guarantees

 	
  

 	
 12

 
	
  

 	
  

 	
  

 	
  

 	
  

 	
  

 
	
  

 	
 SECTION 2.5.

 	
  

 	
 Application of the Article
 of the Indenture Regarding Redemption of Securities

 	
  

 	
 13

 
	
  

 	
  

 	
  

 	
  

 	
  

 	
  

 
	
  

 	
 SECTION 2.6.

 	
  

 	
 Application of the Article
 of the Indenture Relating to a Sinking Fund

 	
  

 	
 13

 
	
  

 	
  

 	
  

 	
  

 	
  

 	
  

 
	
  

 	
 SECTION 2.7.

 	
  

 	
 Additional Events of
 Default

 	
  

 	
 13

 
	
  

 	
  

 	
  

 	
  

 	
  

 	
  

 
	
  

 	
 SECTION 2.8.

 	
  

 	
 Application of the Article
 of the Indenture Regarding Defeasance and Covenant Defeasance

 	
  

 	
 13

 
	
  

 	
  

 	
  

 	
  

 	
  

 	
  

 
	
  

 	
 SECTION 2.9.

 	
  

 	
 Application of the Article
 of the Indenture Regarding Repayment at the Option of Holders

 	
  

 	
 13

 
	
  

 	
  

 	
  

 	
  

 	
  

 	
  

 
	
  

 	
 SECTION 2.10.

 	
  

 	
 Limitations on Subsidiary
 Indebtedness and Preferred Stock

 	
  

 	
 13

 
	
  

 	
  

 	
  

 	
  

 	
  

 	
  

 
	
  

 	
 SECTION 2.11.

 	
  

 	
 Limitations on Liens

 	
  

 	
 14

 
	
  

 	
  

 	
  

 	
  

 	
  

 	
  

 
	
  

 	
 SECTION 2.12.

 	
  

 	
 Repurchase of Notes Upon a
 Change of Control

 	
  

 	
 14

 
	
  

 	
  

 	
  

 	
  

 	
  

 	
  

 
	
  

 	
 SECTION 2.13.

 	
  

 	
 Special Mandatory
 Redemption

 	
  

 	
 15

 
	
  

 	
  

 	
  

 	
  

 	
  

 	
  

 
	
 ARTICLE III. MISCELLANEOUS

 	
  

 	
 16

 
	
  

 	
  

 	
  

 
	
  

 	
 SECTION 3.1.

 	
  

 	
 Governing Law

 	
  

 	
 16

 
	
  

 	
  

 	
  

 	
  

 	
  

 	
  

 
	
  

 	
 SECTION 3.2.

 	
  

 	
 Separability

 	
  

 	
 16

 

i

	
  

 	
  

 	
  

 	
  

 	
  

 	
  

 
	
  

 	
 SECTION 3.3.

 	
  

 	
 Counterparts

 	
  

 	
 16

 
	
  

 	
  

 	
  

 	
  

 	
  

 	
  

 
	
  

 	
 SECTION 3.4.

 	
  

 	
 Ratification

 	
  

 	
 16

 
	
  

 	
  

 	
  

 	
  

 	
  

 	
  

 
	
  

 	
 SECTION 3.5.

 	
  

 	
 Waiver of Jury Trial

 	
  

 	
 17

 
	
  

 	
  

 	
  

 	
  

 	
  

 	
  

 
	
  

 	
 SECTION 3.6.

 	
  

 	
 Force Majeure

 	
  

 	
 17

 
	
  

 	
  

 	
  

 	
  

 	
  

 	
  

 
	
  

 	
 SECTION 3.7.

 	
  

 	
 Effectiveness

 	
  

 	
 17

 
	
  

 	
  

 	
  

 	
  

 	
  

 	
  

 
	
 EXHIBIT A — Form of 3.200%
 Senior Note due 2016

 	
  

 	
 A-1

 
	
  

 	
  

 	
  

 
	
 EXHIBIT B — Form of 4.700%
 Senior Note due 2021

 	
  

 	
 B-1

 
	
  

 	
  

 	
  

 
	
 EXHIBIT C — Form of
 Floating Rate Senior Note due 2014

 	
  

 	
 C-1

 
	
  

 	
  

 	
  

 
	
 EXHIBIT D — Form of
 Additional Subsidiary Guarantee

 	
  

 	
 D-1

 

ii

FOURTEENTH SUPPLEMENTAL INDENTURE

                    SUPPLEMENTAL
INDENTURE (this “Fourteenth Supplemental Indenture”), dated as of March 24,
2011 among QUEST DIAGNOSTICS INCORPORATED, a Delaware corporation (the
“Company”), THE BANK OF NEW YORK MELLON, a New York banking corporation, as
Trustee (the “Trustee”), and the subsidiary guarantors party hereto. 

RECITALS OF THE COMPANY

                    WHEREAS,
the Company, the Trustee and the Initial Subsidiary Guarantors executed and
delivered an Indenture, dated as of June 27, 2001 (the “Base Indenture”), as
supplemented by the First Supplemental Indenture, dated as of June 27, 2001 (
the “First Supplemental Indenture”), as further supplemented by the Second
Supplemental Indenture, dated as of November 26, 2001 (the “Second Supplemental
Indenture”), as further supplemented by the Third Supplemental Indenture, dated
as of April 4, 2002 (the “Third Supplemental Indenture”), as further
supplemented by the Fourth Supplemental Indenture, dated as of March 19, 2003
(the “Fourth Supplemental Indenture”), as further supplemented by the Fifth
Supplemental Indenture, dated as of April 16, 2004 (the “Fifth Supplemental
Indenture”), as further supplemented by the Sixth Supplemental Indenture, dated
as of October 31, 2005 (the “Sixth Supplemental Indenture”), as further
supplemented by the Seventh Supplemental Indenture, dated as of November 21,
2005 (the “Seventh Supplemental Indenture”), as further supplemented by the
Eighth Supplemental Indenture, dated as of July 31, 2006 (the “Eighth
Supplemental Indenture”), as further supplemented by a Ninth Supplemental
Indenture, dated as of September 30, 2006 (the “Ninth Supplemental Indenture”),
as further supplemented by the Tenth Supplemental Indenture, dated as of June
22, 2007 (the “Tenth Supplemental Indenture”), as further supplemented by the
Eleventh Supplemental Indenture, dated as of June 22, 2007 (the “Eleventh
Supplemental Indenture”), as further supplemented by the Twelfth Supplemental
Indenture, dated as of June 25, 2007 (the “Twelfth Supplemental Indenture”), as
further supplemented by the Thirteenth Supplemental Indenture, dated as of
November 17, 2009 (the “Thirteenth Supplemental Indenture”), and as further
supplemented by this Fourteenth Supplemental Indenture (the “Fourteenth
Supplemental Indenture” and, collectively, the “Indenture”), to provide for the
issuance by the Company from time to time of Securities to be issued in one or
mores series as provided in the Indenture; 

                    WHEREAS,
the issuance and sale of $300,000,000 aggregate principal amount of a new
series of the Company’s 3.200% Senior Notes due April 1, 2016 guaranteed by the
Subsidiary Guarantors (the “Notes due 2016”), $550,000,000 aggregate principal
amount of a new series of the Company’s 4.700% Senior Notes due April 1, 2021
guaranteed by the Subsidiary Guarantors (the “Notes due 2021”) and $200,000,000
aggregate principal amount of a new series of the Company’s Floating Rate
Senior Notes due March 24, 2014 guaranteed by the Subsidiary Guarantors (the
“Floating Rate Notes”, and together with the Notes due 2016 and the Notes due
2021, the “Notes”) pursuant to this Fourteenth Supplemental Indenture have been
authorized by resolutions adopted by the Board of Directors of the Company and
the Subsidiary Guarantors; 

1

                    WHEREAS,
the Company desires to issue and sell $1,050,000,000 aggregate principal amount
of the Notes pursuant to this Fourteenth Supplemental Indenture on the date
hereof; 

                    WHEREAS,
Sections 901(7) and 901(9) of the Indenture provide that without the consent of
the Holders of the Securities of any series issued under the Indenture, the
Company and the Subsidiary Guarantors, when authorized by a Board Resolution,
and the Trustee may enter into one or more indentures supplemental to the
Indenture to (a) establish the form or terms of Securities of any series and
any related coupons as permitted by Sections 201 and 301, including the
provisions and procedures relating to Securities convertible into or
exchangeable for any securities of any Person (including the Company) and (b)
cure any ambiguity, to correct or supplement any provision herein which may be
inconsistent with any other provision herein, or make any other provisions with
respect to matters or questions arising under the Base Indenture; 

                    WHEREAS,
the Company and the Subsidiary Guarantors desire to establish the form and
terms of the Notes; 

                    WHEREAS,
all things necessary to make this Fourteenth Supplemental Indenture a valid
supplement to the Indenture according to its terms and the terms of the
Indenture have been done; 

                    NOW,
THEREFORE, for and in consideration of the premises stated herein and the
purchase of the Notes by the Holders thereof, the parties hereto herby enter
into this Fourteenth Supplemental Indenture, for the equal and proportionate
benefit of all Holders of the Notes, as follows: 

ARTICLE I.

DEFINITIONS

                    SECTION
1.1. Certain Terms Defined in the Indenture. 

                    All
capitalized terms used but not defined herein shall have the meanings ascribed
to such terms in the Indenture, as amended hereby, other than such terms as are
defined in the Second Supplemental Indenture. 

                    SECTION
1.2. Definitions. 

                    Except
as may be provided in a Future Supplemental Indenture, for the benefit of the
Holders of the Notes, Section 101 of the Indenture shall be amended by adding
the following new definitions: 

          “Change
of Control” means the occurrence of any of the following: (1) the consummation
of any transaction (including, without limitation, any merger or consolidation)
the result of which is that any “person” (as that term is used in Section 13(d)(3)
of the Exchange Act)(other than the Company or one of its subsidiaries) becomes
the beneficial owner (as defined in Rules 13d-3 and 13d-5 under the Exchange
Act), directly or indirectly, of more than 50% of 

2

the Voting
Stock of the Company or other Voting Stock into which the Voting Stock of the
Company is reclassified, consolidated, exchanged or changed, measured by voting
power rather than number of shares; (2) the direct or indirect sale, transfer,
conveyance or other disposition (other than by way of merger or consolidation),
in one or more series of related transactions, of all or substantially all of
the assets of the Company and the assets of its subsidiaries, taken as a whole,
to one or more “persons” (as that term is used in Section 13(d)(3) of the
Exchange Act)(other than the Company or one of its subsidiaries); or (3) the
first day on which a majority of the members of the Board of Directors of the
Company are not Continuing Directors. Notwithstanding the foregoing, a
transaction will not be deemed to involve a Change of Control if (1) the
Company becomes a direct or indirect wholly-owned subsidiary of a holding
company and (2)(A) the direct or indirect holders of the Voting Stock of such
holding company immediately following that transaction are substantially the
same as the holders of the Voting Stock of the Company immediately prior to
that transaction or (B) immediately following that transaction no person (other
than a holding company satisfying the requirements of this sentence) is the
beneficial owner, directly or indirectly, of more than 50% of the Voting Stock
of such holding company. 

          “Change
of Control Triggering Event” means the occurrence of both a Change of Control
and a Rating Event. 

          
“Continuing Directors” means, as of any date of determination, any member of
the Company’s Board of Directors who (1) was a member of such Board of
Directors on the date the Notes were issued or (2) was nominated for election,
elected or appointed to such Board of Directors with the approval of a majority
of the Continuing Directors who were members of such Board of Directors at the
time of such nomination, election or appointment (either by a specific vote or
by approval of the proxy statement of the Company in which such member was
named as a nominee for election as a director, without objection to such
nomination). 

          “Existing
Receivables Credit Facility” means the receivables-backed financing transaction
pursuant to (1) the Third Amended and Restated Receivables Sales Agreement,
dated as of December 12, 2008 between the Company and each of its direct and
indirect wholly owned Subsidiaries that is a seller thereunder, and Quest
Diagnostics Receivables Inc., as the buyer, (2) the Fourth Amended and Restated
Credit and Security Agreement, dated as of June 11, 2008, as amended, among
Quest Diagnostics Receivables Inc., as borrower, the Company, as initial
servicer, each of the lenders from time to time party thereto, and Bank of
Tokyo Mitsubishi, as administrative agent, and (3) the various related
ancillary documents. 

          “Fitch”
means Fitch Ratings. 

          “Global
Notes” means, individually and collectively, each of Global Notes,
substantially in the form of Exhibits A, B and C. 

          “Global
Notes Legend” means the legend set forth in Section 204 to be placed on all
Global Notes issued under this Indenture. 

          “Initial
Subsidiary Guarantors” means each of American Medical Laboratories
Incorporated, AmeriPath Consolidated Labs, Inc., AmeriPath Florida, LLC,
AmeriPath Group 

3

Holdings,
Inc., AmeriPath Holdings, Inc., AmeriPath Hospital Services Florida, LLC,
AmeriPath Indiana, LLC, AmeriPath Intermediate Holdings, Inc., AmeriPath
Kentucky, Inc., AmeriPath Marketing USA, Inc., AmeriPath Michigan, Inc.,
AmeriPath Mississippi, Inc., AmeriPath New York, LLC, AmeriPath North Carolina,
Inc., AmeriPath Ohio, Inc., AmeriPath Pennsylvania, LLC, AmeriPath
Philadelphia, Inc., AmeriPath SC, Inc., AmeriPath Texas, L.P., AmeriPath
Wisconsin, LLC, AmeriPath Youngstown Labs, Inc., AmeriPath, Inc., AmeriPath,
LLC, Anatomic Pathology Services, Inc., API No. 2, LLC, APL Properties Limited
Liability Company, Arizona Pathology Group, Inc., Central Plains Holdings,
Inc., Dermatopathology Services, Inc., Diagnostic Pathology Management
Services, LLC, Diagnostic Reference Services Inc., DPD Holdings, Inc., Enterix
Inc., ExamOne World Wide of NJ, Inc., ExamOne World Wide, Inc., Focus
Diagnostics, Inc., Focus Technologies Holding Company, HemoCue, Inc., Kailash
B. Sharma, M.D., Inc., LabOne of Ohio, Inc., LabOne, Inc., MedPlus, Inc.,
MetWest Inc., Nichols Institute Diagnostics, Ocmulgee Medical Pathology
Association, Inc., O’Quinn Medical Pathology Association, LLC, Osborn Group
Inc., Pathology Building Partnership, PCA of Denver, Inc., PCA of Nashville,
Inc., Peter G. Klacsmann, M.D., Inc., Quest Diagnostics Clinical Laboratories,
Inc., Quest Diagnostics Finance Incorporated, Quest Diagnostics Holdings
Incorporated, Quest Diagnostics Incorporated (MD), Quest Diagnostics Incorporated
(MI), Quest Diagnostics Incorporated (NV), Quest Diagnostics Investments
Incorporated, Quest Diagnostics LLC (CT), Quest Diagnostics LLC (IL), Quest
Diagnostics LLC (MA), Quest Diagnostics Nichols Institute (f/k/a Quest
Diagnostics Incorporated) (CA), Quest Diagnostics Nichols Institute, Inc.,
Quest Diagnostics of Pennsylvania Inc., Regional Pathology Consultants, LLC,
Rocky Mountain Pathology, LLC, Sharon G. Daspit, M.D., Inc., Shoals Pathology
Associates, Inc., Specialty Laboratories, Inc., Strigen, Inc., TID Acquisition
Corp., and Unilab Corporation. 

          “Investment
Grade Rating” means a rating equal to or higher than Baa3 (or the equivalent)
by Moody’s, BBB- (or the equivalent) by S&P and BBB- (or the equivalent) by
Fitch, and the equivalent investment grade credit rating from any additional
rating agency or Rating Agencies selected by the Company. 

          “Moody’s”
means Moody’s Investors Service, Inc. 

          “Rating
Agencies” means (1) each of Moody’s, S&P and Fitch; and (2) if any of
Moody’s, S&P or Fitch ceases to rate the Notes or fails to make a rating of
the Notes publicly available for reasons outside of the control of the Company,
a “nationally recognized statistical rating organization” within the meaning of
Rule 15c3-1(c)(2)(vi)(F) under the Exchange Act selected by the Company (as
certified by a resolution of the Board of Directors of the Company) as a
replacement agency for Moody’s, S&P or Fitch, or all of them, as the case
may be. 

          “Rating
Event” means the rating on the Notes is lowered by at least two of the Rating
Agencies and the Notes are rated below an Investment Grade Rating by at least
two of the Rating Agencies on any day within the 60-day period (which 60-day
period shall be extended so long as the rating of the Notes is under publicly
announced consideration for possible downgrade by any of the Rating Agencies)
after the earlier of (1) the occurrence of a Change of Control and (2) public
notice of the occurrence of a Change of Control or the intention of the Company
to effect a Change of Control; provided, however, that a Rating Event otherwise
arising by virtue of a particular reduction in rating will not be deemed to
have occurred in respect of a particular Change of Control (and thus will not
be deemed a Rating Event for purposes of the definition of 

4

Change of
Control Triggering Event) if the Rating Agencies making the reduction in rating
to which this definition would otherwise apply do not announce or publicly
confirm or inform the trustee in writing at its request or the request of the
Company that the reduction was the result, in whole or in part, of any event or
circumstance comprised of or arising as a result of, or in respect of, the
applicable Change of Control (whether or not the applicable Change of Control
has occurred at the time of the Rating Event). 

          “S&P”
means Standard & Poor’s Ratings Services, a division of The McGraw-Hill
Companies, Inc. 

          “Voting
Stock” means, with respect to any specified “person” (as that term is used in
Section 13(d)(3) of the Exchange Act) as of any date, the capital stock of such
person that is at the time entitled to vote generally in the election of the
board of directors of such person. 

                    SECTION
1.3. Other Definitions. 

	
  

 	
  

 	
  

 	
  

 	
  

 
	
 Term

 	
  

 	
 Defined in
 Section

 	
  

 
	

 

 	
  

 	

 

 	
  

 
	
 “Additional
 Notes”

 	
  

 	
  

 	
 2.2(a)

 	
  

 
	
 “Business
 Day”

 	
  

 	
  

 	
 2.2(b)

 	
  

 
	
 “Calculation
 Agent”

 	
  

 	
  

 	
 2.2(b)

 	
  

 
	
 “Change of
 Control Offer”

 	
  

 	
  

 	
 2.12

 	
  

 
	
 “Change of
 Control Payment”

 	
  

 	
  

 	
 2.12

 	
  

 
	
 “Change of
 Control Payment Date”

 	
  

 	
  

 	
 2.12

 	
  

 
	
 “Depository”

 	
  

 	
  

 	
 2.1(a)

 	
  

 
	
 “Initial
 Interest Period”

 	
  

 	
  

 	
 2.2(b)

 	
  

 
	
 “Interest
 Determination Date”

 	
  

 	
  

 	
 2.2(b)

 	
  

 
	
 “Interest
 Reset Date”

 	
  

 	
  

 	
 2.2(b)

 	
  

 
	
 “Interest
 Reset Period”

 	
  

 	
  

 	
 2.2(b)

 	
  

 
	
 “London
 business day”

 	
  

 	
  

 	
 2.2(b)

 	
  

 
	
 “Maturity”

 	
  

 	
  

 	
 2.2(b)

 	
  

 
	
 “Reuters
 Screen LIBOR01 Page”

 	
  

 	
  

 	
 2.2(b)

 	
  

 
	
 “Special
 Mandatory Redemption Date”

 	
  

 	
  

 	
 2.13(b)

 	
  

 
	
 “Stock
 Purchase and Sale Agreement”

 	
  

 	
  

 	
 2.13(a)

 	
  

 

ARTICLE II.

FORM AND TERMS OF THE NOTES

                    SECTION
2.1. Form and Dating. 

                    The
Notes due 2016, the applicable Subsidiary Guarantees and the Trustee’s
certificate of authentication shall be substantially in the form of Exhibit
A attached hereto. The Notes due 2021, the applicable Subsidiary Guarantees
and the Trustee’s certificate of authentication shall be substantially in the
form of Exhibit B attached hereto. The Floating Rate Notes, the
applicable Subsidiary Guarantees and the Trustee’s certificate of
authentication shall be substantially in the form of Exhibit C attached
hereto. The Notes shall be executed on behalf 

5

of the Company
by its Chief Executive Officer, the Chief Financial Officer, the Controller or
the Treasurer, and the Secretary, under its corporate seal reproduced thereon.
The Notes may have notations, legends or endorsements required by law, stock
exchange rules or usage. Each Note shall be dated the date of its
authentication. The Notes and any beneficial interest in the Notes shall be in
minimum denominations of $2,000 and integral multiples of $1,000 in excess
thereof. 

                    The
terms and notations contained in the Notes shall constitute, and are hereby
expressly made, a part of this Indenture and the Company, the Subsidiary
Guarantors and the Trustee, by their execution and delivery of this Indenture,
expressly agree to such terms and provisions and to be bound thereby. 

	
  

 	
  

 
	
  

 	
           (a)
 Global Notes. The Global Notes of each series designated herein shall be
 issued initially in the form of one or more fully registered global notes,
 which shall be deposited on behalf of the purchasers of the Notes represented
 thereby with the Depository Trust Company, New York, New York (the
 “Depository”) and registered in the name of Cede & Co., the Depository’s
 nominee, duly executed by the Company, authenticated by the Trustee and with
 guarantees endorsed thereon as hereinafter provided. The aggregate principal
 amount of outstanding Notes may from time to time be increased or decreased
 by adjustments made on the records of the Trustee and the Depository or its
 nominee as hereinafter provided. 

 
	
  

 	
  

 
	
  

 	
           The
 Global Notes may not be transferred except by the Depository, in whole and
 not in part, to another nominee of the Depository or to a successor of the
 Depository or its nominee. If at any time the Depository for the Notes
 notifies the Company that the Depository is unwilling or unable to continue
 as Depository for the Global Notes and a successor Depository for the Global
 Notes is not appointed by the Company within 90 days after delivery of such
 notice, then the Company shall execute, and the Trustee shall, upon receipt
 of a Company Order, for authentication, authenticate and deliver, Definitive
 Notes in an aggregate principal amount equal to the principal amount of the
 Global Notes in exchange for such Global Note. 

 
	
  

 	
  

 
	
  

 	
           (b)
 Book-Entry Provisions. This Section 2.1(b) shall apply only to the Global
 Notes deposited with or on behalf of the Depository. 

 
	
  

 	
  

 
	
  

 	
           The
 Company shall execute and the Trustee shall, in accordance with this Section
 2.1(b), authenticate and deliver the Global Notes that shall be registered in
 the name of the Depository or the nominee of the Depository and shall be
 delivered by the Trustee to the Depository or pursuant to the Depository’s
 instructions. 

 
	
  

 	
  

 
	
  

 	
           Depository
 Participants shall have no rights either under this Indenture or with respect
 to any Global Notes held on their behalf by the Depository or under such
 Global Notes. The Depository shall be treated by the Company, the Subsidiary
 Guarantors, the Trustee and any agent of the Company, the Subsidiary Guarantors
 or the Trustee as the absolute owner of such Global Note for all purposes
 under this Indenture. Notwithstanding the foregoing, nothing herein shall
 prevent the Company or the Trustee from giving effect to any written
 certification, proxy or other authorization furnished by the Depository or
 impair, as between the Depository and the Depository Participants, the 

 

6

	
  

 	
  

 
	
  

 	
 operation of
 customary practices of such Depository governing the exercise of the rights
 of an owner of a beneficial interest in the Global Notes. 

 
	
  

 	
  

 
	
  

 	
           (c)
 Definitive Notes. Notes issued in certificated form shall be substantially in
 the form of Exhibit A, Exhibit B or Exhibit C as applicable, attached hereto,
 but without including the text referred to therein as applying only to Global
 Notes. Except as provided above in subsection (a), owners of beneficial
 interests in the Global Notes will not be entitled to receive physical
 delivery of certificated Notes. 

 
	
  

 	
  

 
	
  

 	
           (d)
 Transfer and Exchange of the Notes. The transfer and exchange of beneficial
 interests in the Global Notes shall be effected through the Depository, in
 accordance with this Indenture and the procedures of the Depository therefor.
 Beneficial interests in the Global Notes may be transferred to Persons who
 take delivery thereof in the form of a beneficial interest in the Global
 Notes. 

 
	
  

 	
  

 
	
  

 	
           (e)
 Paying Agent. The Company appoints The Bank of New York Mellon as agent of
 the Company for the payment of the principal of (and premium, if any) and
 interest on the Notes; and that the Corporate Trust Office of The Bank of New
 York Mellon in the Borough of Manhattan, the City of New York, be and hereby
 is, designated as the office or agency in the Borough of Manhattan where the
 Notes may be presented for payment and where notices to or demands upon the
 Company in respect of the Notes and the Indenture pursuant to which the Notes
 are to be issued may be served. 

 

                    SECTION
2.2. Terms of the Notes. 

	
  

 	
  

 
	
  

 	
           (a)
 The following terms relating to the Notes due 2016 and Notes due 2021 are
 hereby established: 

 

	
  

 	
  

 
	
  

 	
           (1)
 The Notes due 2016 shall constitute a series of Securities having the title
 “Senior Notes due 2016”. The Notes due 2021 shall constitute a separate
 series of Securities having the title “Senior Notes due 2021”. 

 
	
  

 	
  

 
	
  

 	
           (2)
 The aggregate principal amount of the Notes due 2016 that may be initially
 authenticated and delivered under the Indenture (except for Notes due 2016
 authenticated and delivered upon registration of, transfer of, or in exchange
 for, or in lieu of, other Notes due 2016 pursuant to Sections 304, 305, 306,
 906 or 1107 of the Indenture) shall be $300,000,000. The aggregate principal
 amount of the Notes due 2021 that may be initially authenticated and
 delivered under the Indenture (except for Notes due 2021 authenticated and
 delivered upon registration of, transfer of, or in exchange for, or in lieu
 of, other Notes due 2021 pursuant to Sections 304, 305, 306, 906 or 1107 of
 the Indenture) shall be $550,000,000. The Company may from time to time,
 without the consent of the Holders of Notes of any series, issue additional
 Notes due 2016 and Notes due 2017 (in any such case “Additional Notes”) of
 any series having the same ranking and the same interest rate, maturity and
 other terms as the Notes of that series. Any Additional Notes of a series and
 the existing Notes of that series will 

 

7

	
  

 	
  

 
	
  

 	
 constitute a
 single series under the Indenture and all references to the relevant Notes
 shall include the Additional Notes unless the context otherwise requires. 

 
	
  

 	
  

 
	
  

 	
           (3)
 The entire outstanding principal of the Notes due 2016 shall be payable on
 April 1, 2016. The entire outstanding principal of the Notes due 2021 shall
 be payable on April 1, 2021. 

 
	
  

 	
  

 
	
  

 	
           (4)
 The rate at which the Notes due 2016 shall bear interest shall be 3.200% per
 annum and the rate at which the Notes due 2021 shall bear interest shall be
 4.700% per annum; the date from which interest shall accrue on the Notes due
 2016 and the Notes due 2021 shall be March 24, 2011, or the most recent
 Interest Payment Date to which interest has been paid or provided for; the
 Interest Payment Dates for the Notes due 2016 and the Notes due 2021 shall be
 April 1 and October 1 of each year, beginning October 1, 2011; the interest
 so payable, and punctually paid or duly provided for, on any Interest Payment
 Date, will be paid, in immediately available funds, to the Persons in whose
 names the Notes (or one or more Predecessor Securities) is registered at the
 close of business on the Regular Record Date for such interest, which shall
 be March 15 or September 15, as the case may be, next preceding such Interest
 Payment Date. Interest on the Notes due 2016 and the Notes due 2021 will be
 computed on the basis of a 360-day year of twelve 30-day months. Any such
 interest not punctually paid or duly provided for shall forthwith cease to be
 payable to the respective Holders on such Regular Record Date, and such
 Defaulted Interest, may be paid to the Persons in whose names the Notes (or
 one or more Predecessor Securities) is registered at the close of business on
 a Special Record Date for the payment of such Defaulted Interest to be fixed
 by the Trustee, notice whereof shall be given to Holders of Notes not less
 than 10 days prior to such Special Record Date, or may be paid at any time in
 any other lawful manner not inconsistent with requirements of any securities
 exchange on which the Notes may be listed, and upon such notice as may be
 required by such exchange, all as more fully provided in said Indenture.
 Payment of principal and interest on the Notes will be made at the Corporate
 Trust Office of the Trustee or such other office or agency of the Company as
 may be designated for such purpose, in such coin or currency of the United
 States of America as at the time of payment is legal tender for payment of
 public and private debts; provided, however, that each installment of
 interest and principal on the Notes may at the Company’s option be paid in
 immediately available funds by transfer to an account maintained by the payee
 located in the United States. 

 
	
  

 	
  

 
	
  

 	
           (5)
 Each of the Notes due 2016 and the Notes due 2021 shall be issuable in whole
 in the registered form of one or more Global Notes (without coupons), and the
 Depository for such Global Notes shall be the Depository Trust Company, New
 York, New York. 

 
	
  

 	
  

 
	
  

 	
           (6)
 The Redemption Amount of Basis Points applicable to the Notes used to
 calculate the Redemption Price pursuant to Section 1108 of this Indenture
 shall be 20 basis points for the Notes due 2016 and 25 basis points for the
 Notes due 2021. 

 

8

	
  

 	
  

 
	
  

 	
           (7)
 Each of the Notes due 2016 and the Notes due 2021 shall be guaranteed by the
 Initial Subsidiary Guarantors in accordance with Article Sixteen of the
 Indenture. 

 

	
  

 	
  

 
	
  

 	
           (b)
 The following terms relating to the Floating Rate Notes are hereby
 established: 

 

	
  

 	
  

 
	
  

 	
           (1)
 The Floating Rate Notes shall constitute a separate series of Securities
 having the title “Floating Rate Senior Notes due 2014.” 

 
	
  

 	
  

 
	
  

 	
           (2)
 The aggregate principal amount of the Floating Rate Notes that may be
 initially authenticated and delivered under the Indenture (except for
 Floating Rate Notes authenticated and delivered upon registration of, transfer
 of, or in exchange for, or in lieu of, other Floating Rate Notes pursuant to
 Sections 304, 305, 306, 906 or 1107 of the Indenture) shall be $200,000,000.
 The Company may from time to time, without the consent of the Holders of
 Notes of any series, issue additional Floating Rate Notes (in any such case
 “Additional Notes”) of any series having the same ranking and the same
 interest rate, maturity and other terms as the Notes of that series. Any
 Additional Notes of a series and the existing Notes of that series will
 constitute a single series under the Indenture and all references to the
 relevant Notes shall include the Additional Notes unless the context
 otherwise requires. 

 
	
  

 	
  

 
	
  

 	
           (3)
 The entire outstanding principal of the Floating Rate Notes shall be payable
 on March 24, 2014. 

 
	
  

 	
  

 
	
  

 	
           (4)
 The Floating Rate Notes shall be issuable in whole in the registered form of
 one or more Global Notes (without coupons), and the Depository for such
 Global Notes shall be the Depository Trust Company, New York, New York. 

 
	
  

 	
  

 
	
  

 	
           (5)
 The Floating Rate Notes shall bear interest at a per annum rate equal to
 three-month LIBOR (as defined below) for the applicable Interest Reset Period
 or Initial Interest Period (each as defined below) plus 85 basis points; the
 date from which interest shall accrue on the Floating Rate Notes shall be
 March 24, 2011, or the most recent Interest Payment Date to which interest
 has been paid or provided for. Interest on the Floating Rate Notes will be
 computed on the basis of the actual number of days elapsed over a 360-day
 year. 

 
	
  

 	
  

 
	
  

 	
           (6)
 The Interest Payment Dates for the Floating Rate Notes shall be March 24,
 June 24, September 24 and December 24 of each year, beginning June 24, 2011;
 the interest so payable, and punctually paid or duly provided for, on any
 Interest Payment Date, will be paid, in immediately available funds, to the
 Persons in whose names the Notes (or one or more Predecessor Securities) is
 registered at the close of business on the Regular Record Date for such
 interest, which shall be March 9, June 9, September 9 and December 9, as the
 case may be, next preceding such Interest Payment Date. If any Interest
 Payment Date (other than the Maturity date) is not a Business Day at the
 relevant place of payment, the 

 

9

	
  

 	
  

 
	
  

 	
 Company will
 pay interest on the next day that is a Business Day at such place of payment
 as if payment were made on the date such payment was due, and no interest
 will accrue on the amounts so payable for the period from and after such date
 to the immediately succeeding Business Day, except that if such Business Day
 is in the immediately succeeding calendar month, such Interest Payment Date
 (other than the Maturity date) shall be the immediately preceding Business
 Day. If the Maturity date of the Floating Rate Notes is not a Business Day at
 the relevant place of payment, the Company will pay interest, if any, and
 principal and premium, if any, on the next day that is a Business Day at such
 place of payment as if payment were made on the date such payment was due,
 and no interest will accrue on the amounts so payable for the period from and
 after such date to the immediately succeeding Business Day. 

 
	
  

 	
  

 
	
  

 	
           (7)
The interest rate on the Floating Rate Notes shall be reset quarterly on
March 24, June 24, September 24 and December 24 of each year, as applicable,
commencing June 24, 2011 (each, an “Interest Reset Date”). The “Initial
Interest Period” will be the period from and including the original issue
date to but excluding the initial Interest Reset Date. Thereafter, each
“Interest Reset Period” will be the period from and including an Interest
Reset Date to but excluding the immediately succeeding Interest Reset Date;
provided that the final Interest Reset Period for the Floating Rate Notes
will be the period from and including the Interest Reset Date immediately
preceding the Maturity date of such Floating Rate Notes to but excluding the
Maturity date.  

 
	
  

 	
  

 
	
  

 	
                     If
 any Interest Reset Date would otherwise be a day that is not a Business Day,
 the Interest Reset Date will be postponed to the immediately succeeding day
 that is a Business Day, except that if that business day is in the
 immediately succeeding calendar month, the Interest Reset Date shall be the
 immediately preceding Business Day. 

 
	
  

 	
  

 
	
  

 	
                     The
 interest rate in effect on each day will be (i) if that day is an Interest
 Reset Date, the interest rate determined as of the Interest Determination
 Date (as defined below) immediately preceding such Interest Reset Date or
 (ii) if that day is not an Interest Reset Date, the interest rate determined
 as of the Interest Determination Date immediately preceding the most recent
 Interest Reset Date or the original issue date, as the case may be. 

 
	
  

 	
  

 
	
  

 	
           (8)
 The interest rate applicable to each Interest Reset Period commencing on the
 related Interest Reset Date, or the original issue date in the case of the
 Initial Interest Period, will be the rate determined as of the applicable
 Interest Determination Date. The “Interest Determination Date” will be the
 second London business day immediately preceding the original issue date, in
 the case of the initial Interest Reset Period, or thereafter the applicable
 Interest Reset Date. 

 

	
  

 	
  

 
	
  

 	
                     Three-month
 LIBOR shall be determined by the Calculation Agent as of the applicable
 Interest Determination Date in accordance with the following provisions: 

 

10

	
  

 	
  

 
	
  

 	
 (i) LIBOR is
 the rate for deposits in U.S. dollars for the 3-month period which appears on
 Reuters Screen LIBOR01 Page (as defined below) at approximately 11:00 a.m.,
 London time, on the applicable Interest Determination Date. “Reuters Screen
 LIBOR01 Page” means the display designated on page “LIBOR01” on Reuters
 Screen (or such other page as may replace the LIBOR01 page on that service,
 any successor service or such other service or services as may be nominated
 by the British Bankers’ Association for the purpose of displaying London
 interbank offered rates for U.S. dollar deposits). If no rate appears on
 Reuters Screen LIBOR01 Page, LIBOR for such Interest Determination Date will
 be determined in accordance with the provisions of Section 2.2(b)(8)(ii). 

 
	
  

 	
  

 
	
  

 	
      (ii)
 With respect to an Interest Determination Date on which no rate appears on
 Reuters Screen LIBOR01 Page as of approximately 11:00 a.m., London time, on
 such Interest Determination Date, the Calculation Agent shall request the
 principal London offices of each of four major reference banks (which may
 include affiliates of the underwriters) in the London interbank market
 selected by the Calculation Agent (after consultation with the Company) to
 provide the Calculation Agent with a quotation of the rate at which deposits
 of U.S. dollars having a three-month Maturity, commencing on the second
 London business day immediately following such Interest Determination Date,
 are offered by it to prime banks in the London interbank market as of
 approximately 11:00 a.m., London time, on such Interest Determination Date in
 a principal amount equal to an amount of not less than U.S. $1,000,000 that
 is representative for a single transaction in such market at such time. If at
 least two such quotations are provided, LIBOR for such Interest Determination
 Date will be the arithmetic mean of such quotations as calculated by the
 Calculation Agent. If fewer than two quotations are provided, LIBOR for such
 Interest Determination Date will be the arithmetic mean of the rates quoted
 as of approximately 11:00 a.m., New York City time, on such Interest Determination
 Date by three major banks (which may include affiliates of the underwriters)
 selected by the Calculation Agent (after consultation with the Company) for
 loans in U.S. dollars to leading European banks having a three-month Maturity
 commencing on the second London business day immediately following such
 Interest Determination Date and in a principal amount equal to an amount of
 not less than U.S. $1,000,000 that is representative for a single transaction
 in such market at such time; provided, however, that if the banks selected as
 aforesaid by the Calculation Agent are not quoting such rates as mentioned in
 this sentence, LIBOR for such Interest Determination Date will be LIBOR
 determined with respect to the immediately preceding Interest Determination Date.
 

 

	
  

 	
  

 
	
  

 	
                          All
 percentages resulting from any calculation of any interest rate for the
 Floating Rate Notes will be rounded, if necessary, to the nearest one hundred
 thousandth of a percentage point, with five one-millionths of a percentage
 point rounded 

 

11

	
  

 	
  

 
	
  

 	
 upward
 (e.g., 9.876545% (or .09876545) would be rounded to 9.87655% (or .0987655)),
 and all dollar amounts will be rounded to the nearest cent, with one-half
 cent being rounded upward. 

 
	
  

 	
  

 
	
  

 	
                     Promptly
 upon such determination, the Calculation Agent shall notify the Company and
 the Trustee (if the Calculation Agent is not the Trustee) of the interest
 rate for the new Interest Reset Period. Upon request of a holder of the
 Floating Rate Notes, the Calculation Agent will provide to such holder the
 interest rate in effect on the date of such request and, if determined, the
 interest rate for the next Interest Reset Period. All calculations made by
 the Calculation Agent for the purposes of calculating interest on the Floating
 Rate Notes shall be conclusive and binding on the holders and the Company,
 absent manifest errors. 

 

                              For
purposes of Section 2.2(b) of this Fourteenth Supplemental Indenture, “Business
Day” means any day (1) that is not a Saturday or Sunday and that is not a day
on which banking institutions are authorized or obligated by law or executive
order to close in The City of New York and, for any place of payment outside of
The City of New York, in such place of payment, and (2) that is also a “London
business day,” which is a day on which dealings in deposits in U.S. dollars are
transacted in the London interbank market. 

                              For
purposes of Section 2.2(b) of this Fourteenth Supplemental Indenture, the term
“Calculation Agent” means The Bank of New York Mellon, or its successor
appointed by the Company. All of the benefits, protections, privileges,
immunities, indemnities, and rights under the Indenture that apply to the
Trustee also apply to The Bank of New York Mellon, in its individual capacity
and in its capacity as Calculation Agent hereunder. 

                              For
purposes of Section 2.2(b) of this Fourteenth Supplemental Indenture, the term
“Maturity,” means the date on which the principal of such Floating Rate Note or
an installment of principal becomes due and payable as therein provided or as
provided in the Indenture, whether at the Stated Maturity or by declaration of
acceleration, call for redemption, repayment or otherwise. 

	
  

 	
  

 
	
  

 	
            (9)
 The Floating Rate Notes shall be guaranteed by the Initial Subsidiary
 Guarantors in accordance with Article Sixteen of the Indenture. 

 
	
  

 	
  

 
	
  

 	
 SECTION 2.3.
 [RESERVED]

 
	
  

 	
  

 
	
                     SECTION
 2.4. Application of the Article of the Indenture Regarding Guarantees.
 

 
	
  

 	
  

 
	
                               Except
 as may be provided in a Future Supplemental Indenture, the provisions of
 Article Sixteen of the Indenture, as amended, shall apply to the Notes. 

 

12

                    SECTION
2.5. Application of the Article of the Indenture Regarding Redemption of
Securities.

	
  

 	
  

 
	
  

 	
                     Except
 as may be provided in a Future Supplemental Indenture, the provisions of
 Article Eleven of the Indenture, as amended, shall apply to the Notes due 2016 and the Notes due 2021.

 

                    SECTION
2.6. Application of the Article of the Indenture Relating to a Sinking Fund.

                    Except
as may be provided in a Future Supplemental Indenture, none of the Notes shall
be entitled to the benefit of any sinking fund, and the provisions of the
Indenture relating to a sinking fund, including Article Twelve and
Subsection (3) of Section 501 of the Indenture, shall not apply to
any of the Notes.

                    SECTION
2.7. Additional Events of Default.

                    Except
as may be provided by a Future Supplemental Indenture, for the benefit of the
holders of the Notes, Section 501(7)(A) of the Indenture shall be amended
by deleting the words “$100 million” in the second line thereof and, in their
place, adding the words “$200 million;” and Section 501(7)(B) of the
Indenture shall be amended by deleting the words “$100 million” in the sixth
line thereof and, in their place, adding the words “$200 million.”

                    SECTION
2.8. Application of the Article of the Indenture Regarding Defeasance and
Covenant Defeasance.

                    Except
as may be provided by a Future Supplemental Indenture, the provisions of
Article Fourteen of the Indenture, including the provisions relating to
defeasance and covenant defeasance of the Securities under Sections 1402
and 1403, respectively, of the Indenture shall apply to the Notes.

                    SECTION
2.9. Application of the Article of the Indenture Regarding Repayment at the
Option of Holders.

                    Except
as may be provided by a Future Supplemental Indenture, the provisions of
Article Thirteen of the Indenture shall not apply to the Notes.

                    SECTION
2.10. Limitations on Subsidiary Indebtedness and Preferred Stock.

	
  

 	
  

 
	
  

 	
           (a)
 Except as may be provided by a Future Supplemental Indenture, for the sole
 benefit of the holders of the Notes, Section 1011(a) of the Indenture shall
 be amended by deleting the words “First Supplemental Indenture” in the second
 line thereof and, in their place, adding the words “Fourteenth Supplemental
 Indenture”.

 
	
  

 	
  

 
	
  

 	
           (b)
 Except as may be provided by a Future Supplemental Indenture, for the sole
 benefit of the holders of the Notes, Section 1011 of the Indenture shall be
 amended by adding a new subsection 1011(k) and subsection 1011(l) as follows:

 

13

	
  

 	
  

 
	
  

 	
                     (k)
 any guarantee of Indebtedness of the Company by any Subsidiary of the Company
 in anticipation of such Subsidiary becoming a Subsidiary Guarantor pursuant
 to Article Sixteen of the Indenture.

 
	
  

 	
  

 
	
  

 	
                     (l)
 shares of Preferred Stock held by the Company or a subsidiary of the Company.

 
	
  

 	
  

 
	
                     SECTION
 2.11. Limitations on Liens.

 
	
  

 	
  

 
	
  

 	
           (a)
 Except as may be provided by a Future Supplemental Indenture, for the sole
 benefit of the holders of the Notes, Section 1008(a) of the Indenture shall
 be amended by deleting the words “First Supplemental Indenture” in the first
 and second line thereof and, in their place, adding the words “Fourteenth
 Supplemental Indenture”.

 
	
  

 	
  

 
	
                     SECTION
 2.12. Repurchase of Notes Upon a Change of Control.

 
	
  

 	
  

 
	
                     Except
 as may be provided by a Future Supplemental Indenture, for the benefit of the
 holders of the Notes, a new Section 315 shall be added to the Indenture as
 follows:

 
	
  

 	
  

 
	
                     Section
 315 Repurchase of Notes Upon a Change of Control.

 
	
  

 	
  

 
	
  

 	
           (a)
 If a Change of Control Triggering Event occurs, unless the Company has
 exercised its option to redeem the Notes as described in Section 1108, the
 Company shall make an offer to repurchase all or any part (equal to $2,000 or
 an integral multiple of $1,000 in excess thereof) of the Notes pursuant to
 the offer described below (the “Change of Control Offer”) on the terms set
 forth in the Notes. In the Change of Control Offer, the Company shall offer
 payment in cash equal to 101% of the aggregate principal amount of Notes
 repurchased, plus accrued and unpaid interest, if any, on the Notes
 repurchased to the date of repurchase (the “Change of Control Payment”).
 Within 30 days following any Change of Control Triggering Event or, at the
 option of the Company, prior to any Change of Control, but after the public
 announcement of the transaction that constitutes or may constitute the Change
 of Control, the Company shall mail a notice to holders of Notes describing
 the transaction that constitutes or may constitute the Change of Control
 Triggering Event and offering to repurchase the Notes on the date specified
 in the notice, which date will be no earlier than 30 days and no later
 than 60 days from the date such notice is mailed (the “Change of Control
 Payment Date”). The notice shall, if mailed prior to the date of consummation
 of the Change of Control, state that the offer to purchase is conditioned on
 the Change of Control Triggering Event occurring on or prior to the Change of
 Control Payment Date. 

 
	
  

 	
  

 
	
  

 	
           (b)
 The Company shall comply with the requirements of Rule 14e-1 under the
 Securities Exchange Act of 1934, as amended, and any other securities laws
 and regulations thereunder to the extent those laws and regulations are
 applicable in connection with the repurchase of the Notes as a result of a
 Change of Control Triggering Event. To the extent that the provisions of any
 such securities laws or regulations conflict with the Change of Control
 provisions of the Notes, the Company will comply with the applicable
 securities laws and regulations and will not be deemed to have 

 

14

	
  

 	
  

 	
  

 
	
  

 	
 breached its obligations under
 the Change of Control provisions of the Notes by virtue of any such conflict.

 
	
  

 	
  

 	
  

 
	
  

 	
           (c)
 On the Change of Control Payment Date, the Company shall, to the extent
 lawful:

 
	
  

 	
  

 	
  

 
	
  

 	
  

 	
           (1)
 accept for payment all Notes or portions of Notes properly tendered pursuant
 to the Change of Control Offer;

 
	
  

 	
  

 	
  

 
	
  

 	
  

 	
           (2)
 deposit with the Paying Agent an amount equal to the Change of Control
 Payment in respect of all Notes or portions of Notes properly tendered; and

 
	
  

 	
  

 	
  

 
	
  

 	
  

 	
           (3)
 deliver or cause to be delivered to the Trustee the Notes properly accepted
 together with an Officers’ Certificate stating the aggregate principal amount
 of Notes or portions of Notes being purchased.

 
	
  

 	
  

 	
  

 
	
  

 	
           (d)
 The Company shall not be required to make a Change of Control Offer upon the
 occurrence of a Change of Control Triggering Event if a third party makes
 such an offer in the manner, at the times and otherwise in compliance with
 the requirements for an offer made by the Company and the third party
 repurchases all Notes properly tendered and not withdrawn under its offer. In
 addition, the Company shall not repurchase any Notes if there has occurred
 and is continuing on the Change of Control Payment Date an event of default
 under this Indenture, other than a default in the payment of the Change of
 Control Payment upon a Change of Control Triggering Event.

 
	
  

 	
  

 	
  

 
	
                     SECTION
 2.13. Special Mandatory Redemption.

 
	
  

 	
  

 	
  

 
	
  

 	
                     Except
 as may be provided in a Future Supplemental Indenture, for the sole benefit
 of the Holders of the Notes due 2021 and the Floating Rate Notes, a new
 Section 1109 shall be added to the Indenture as follows:

 
	
  

 	
  

 	
  

 
	
  

 	
           (a)
 If the Company has failed to consummate the acquisition of Athena
 Diagnostics, Inc. on or prior to October 31, 2011, or the related Stock
 Purchase and Sale Agreement, dated as of February 23, 2011, between Thermo
 Fisher Scientific Inc., a Delaware corporation and the Company (the “Stock
 Purchase and Sale Agreement”) is terminated at any time prior thereto, then
 the Company must redeem all of the Notes due 2021 and the Floating Rate Notes
 on the Special Mandatory Redemption Date (as defined below) at a redemption
 price equal to 101% of the aggregate principal amount of the Notes due 2021
 and the Floating Rate Notes, plus accrued and unpaid interest from the date
 of initial issuance to, but excluding, the Special Mandatory Redemption Date
 (subject to the right of Holders of record on the relevant record date to
 receive interest due on the relevant Interest Payment Date). 

 
	
  

 	
  

 	
  

 
	
  

 	
           (b)
 The “Special Mandatory Redemption Date” means the earlier to occur of (1)
 November 15, 2011, if the acquisition of Athena Diagnostics, Inc. has not
 been completed on or prior to October 31, 2011, or (2) the 30th day (or if
 such day is not a 

 

15

	
  

 	
  

 	
  

 
	
  

 	
 Business
 Day, the first Business Day thereafter) following the termination of the
 Stock Purchase and Sale Agreement for any reason.

 
	
  

 	
  

 
	
  

 	
           (c)
 The Company shall cause notice of special mandatory redemption to be mailed,
 with a copy to the Trustee, within ten Business Days after the occurrence of
 the event triggering redemption to each Holder at its registered address.
 Such notice shall include the information required pursuant to Section 1104
 of the Indenture. If funds sufficient to pay the special mandatory redemption
 price of all Notes due 2021 and the Floating Rate Notes to be redeemed on the
 Special Mandatory Redemption Date are deposited with the Trustee on or before
 such Special Mandatory Redemption Date, plus accrued and unpaid interest, if
 any, to but excluding the Special Mandatory Redemption Date, the Notes due
 2021 and the Floating Rate Notes shall cease to bear interest.

 

ARTICLE III.

MISCELLANEOUS

                    SECTION
3.1. Governing Law.

                    This
Fourteenth Supplemental Indenture and the Notes shall be governed by and
construed in accordance with the laws of the State of New York, without regard
to principles of conflicts of laws. This Fourteenth Supplemental Indenture is
subject to the provisions of the Trust Indenture Act that are required to be
part of this Indenture and shall, to the extent applicable, be governed by such
provisions.

                    SECTION
3.2. Separability.

                    In
case any provision in this Fourteenth Supplemental Indenture or in any
Securities, including the Notes, shall be invalid, illegal or unenforceable,
the validity, legality and enforceability of the remaining provisions shall not
in any way be affected or impaired thereby.

                    SECTION
3.3. Counterparts.

                    This
Fourteenth Supplemental Indenture may be executed in any number of
counterparts, each of which so executed shall be deemed to be an original, but
all such counterparts shall together constitute but one and the same
Supplemental Indenture.

                    SECTION
3.4. Ratification.

                    The
Base Indenture, as supplemented and amended by the First Supplemental
Indenture, the Second Supplemental Indenture, the Third Supplemental Indenture,
the Fourth Supplemental Indenture, the Fifth Supplemental Indenture, the Sixth
Supplemental Indenture, the Seventh Supplemental Indenture, the Eighth
Supplemental Indenture, the Ninth Supplemental Indenture, the Tenth
Supplemental Indenture, the Eleventh Supplemental Indenture, the Twelfth
Supplemental Indenture, the Thirteenth Supplemental Indenture and this
Fourteenth 

16

Supplemental
Indenture is in all respects ratified and confirmed. The Base Indenture, the
First Supplemental Indenture, the Third Supplemental Indenture, the Fourth
Supplemental Indenture, the Fifth Supplemental Indenture, Sixth Supplemental
Indenture, the Seventh Supplemental Indenture, the Eighth Supplemental
Indenture, the Ninth Supplemental Indenture, the Tenth Supplemental Indenture,
the Eleventh Supplemental Indenture, the Twelfth Supplemental Indenture, the
Thirteenth Supplemental Indenture and this Fourteenth Supplemental Indenture
shall be read, taken and construed as one and the same instrument. All
provisions included in this Fourteenth Supplemental Indenture supersede any
conflicting provisions included in the Base Indenture unless not permitted by
law. The Trustee accepts the trusts created by the Indenture, as supplemented
by this Fourteenth Supplemental Indenture, and agrees to perform the same upon
the terms and conditions of the Indenture, as supplemented by this Fourteenth
Supplemental Indenture. 

                    SECTION
3.5. Waiver of Jury Trial . 

                    EACH
OF THE COMPANY AND THE TRUSTEE HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT
PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL
PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE NOTES OR THE
TRANSACTION CONTEMPLATED HEREBY.

                    SECTION
3.6. Force Majeure. 

                    In
no event shall the Trustee be responsible or liable for any failure or delay in
the performance of its obligations hereunder arising out of or caused by,
directly or indirectly, forces beyond its control, including, without
limitation, strikes, work stoppages, accidents, acts of war or terrorism, civil
or military disturbances, nuclear or natural catastrophes or acts of God, and
interruptions, loss or malfunctions of utilities, communications or computer
(software and hardware) services; it being understood that the Trustee shall
use reasonable efforts which are consistent with accepted practices in the
banking industry to resume performance as soon as practicable under the
circumstances.

                    SECTION
3.7. Effectiveness. 

                    The
provisions of this Fourteenth Supplemental Indenture shall become effective as
of the date hereof.

[Remainder of page intentionally left blank.]

17

                    IN
WITNESS WHEREOF, the parties hereto have caused this Fourteenth Supplemental
Indenture to be duly executed, and their respective corporate seals to be
hereunto affixed and attested, all as of the date first above written.

QUEST DIAGNOSTICS INCORPORATED

	
  

 	
  

 	
  

 	
  

 	
  

 
	
  

 	
 By:

 	
  

 	
 /s/ Robert
 O’Keef

 	
  

 
	
  

 	
  

 	

 

 	

 

 	
  

 
	
  

 	
  

 	
  

 	
 Name:  Robert
 O’Keef

 	
  

 
	
  

 	
  

 	
  

 	
 Title:    Vice
 President and Treasurer

 

	
  

 	
  

 
	
  

 	
 AMERICAN
 MEDICAL LABORATORIES, INCORPORATED

 
	
  

 	
 AMERIPATH,
 INC.

 
	
  

 	
 AMERIPATH
 CONSOLIDATED LABS, INC.

 
	
  

 	
 AMERIPATH
 FLORIDA, LLC

 
	
  

 	
 AMERIPATH
 GROUP HOLDINGS, INC.

 
	
  

 	
 AMERIPATH
 HOLDINGS, INC.

 
	
  

 	
 AMERIPATH
 HOSPITAL SERVICES FLORIDA, LLC

 
	
  

 	
 AMERIPATH
 INDIANA, LLC

 
	
  

 	
 AMERIPATH
 INTERMEDIATE HOLDINGS, INC.

 
	
  

 	
 AMERIPATH
 KENTUCKY, INC.

 
	
  

 	
 AMERIPATH
 MARKETING USA, INC.

 
	
  

 	
 AMERIPATH
 MICHIGAN, INC.

 
	
  

 	
 AMERIPATH
 MISSISSIPPI, INC.

 
	
  

 	
 AMERIPATH
 NEW YORK, LLC

 
	
  

 	
 AMERIPATH
 NORTH CAROLINA, INC.

 
	
  

 	
 AMERIPATH
 OHIO, INC.

 
	
  

 	
 AMERIPATH
 PENNSYLVANIA, LLC

 
	
  

 	
 AMERIPATH
 PHILADELPHIA, INC.

 
	
  

 	
 AMERIPATH
 SC, INC.

 
	
  

 	
 AMERIPATH
 TEXAS, L.P.

 
	
  

 	
 AMERIPATH
 YOUNGSTOWN LABS, INC.

 
	
  

 	
 AMERIPATH
 WISCONSIN, LLC

 
	
  

 	
 AMERIPATH,
 LLC

 
	
  

 	
 API NO. 2,
 LLC

 
	
  

 	
 ANATOMIC
 PATHOLOGY SERVICES, INC.

 
	
  

 	
 ARIZONA
 PATHOLOGY GROUP, INC.

 
	
  

 	
 APL PROPERTIES
 LIMITED LIABILITY COMPANY

 
	
  

 	
 CENTRAL
 PLAINS HOLDINGS, INC.

 
	
  

 	
 DERMATOPATHOLOGY
 SERVICES, INC.

 
	
  

 	
 DIAGNOSTIC
 PATHOLOGY MANAGEMENT SERVICES, LLC

 
	
  

 	
 DIAGNOSTIC
 REFERENCE SERVICES, INC.

 
	
  

 	
 DPD
 HOLDINGS, INC.

 
	
  

 	
 ENTERIX INC.

 
	
  

 	
 EXAMONE
 WORLD WIDE, INC.

 
	
  

 	
 EXAMONE
 WORLD WIDE OF NJ, INC.

 
	
  

 	
 FOCUS
 TECHNOLOGIES HOLDING COMPANY

 
	
  

 	
 FOCUS
 DIAGNOSTICS, INC.

 
	
  

 	
 HEMOCUE,
 INC.

 
	
  

 	
 KAILASH B.
 SHARMA, M.D., INC.

 
	
  

 	
 LABONE, INC.

 
	
  

 	
 LABONE OF
 OHIO, INC.

 
	
  

 	
 MEDPLUS,
 INC.

 
	
  

 	
 METWEST INC.

 
	
  

 	
 NICHOLS
 INSTITUTE DIAGNOSTICS

 

	
  

 	
  

 
	
  

 	
 OSBORN GROUP
 INC.

 
	
  

 	
 OCMULGEE
 MEDICAL PATHOLOGY ASSOCIATION, INC.

 
	
  

 	
 O’QUINN
 MEDICAL PATHOLOGY ASSOCIATION, LLC

 
	
  

 	
 PATHOLOGY
 BUILDING PARTNERSHIP

 
	
  

 	
 PCA OF
 DENVER, INC.

 
	
  

 	
 PCA OF
 NASHVILLE, INC.

 
	
  

 	
 PETER G.
 KLACSMANN M.D., INC.

 
	
  

 	
 QUEST DIAGNOSTICS
 HOLDINGS INCORPORATED

 
	
  

 	
 QUEST
 DIAGNOSTICS CLINICAL LABORATORIES, INC.

 
	
  

 	
 QUEST
 DIAGNOSTICS NICHOLS INSTITUTE

 
	
  

 	
 QUEST
 DIAGNOSTICS FINANCE INCORPORATED

 
	
  

 	
 QUEST
 DIAGNOSTICS INVESTMENTS

 
	
  

 	
 INCORPORATED

 
	
  

 	
 QUEST
 DIAGNOSTICS INCORPORATED (NV)

 
	
  

 	
 QUEST DIAGNOSTICS
 INCORPORATED (MD)

 
	
  

 	
 QUEST
 DIAGNOSTICS LLC (IL)

 
	
  

 	
 QUEST
 DIAGNOSTICS LLC (CT)

 
	
  

 	
 QUEST
 DIAGNOSTICS LLC (MA)

 
	
  

 	
 QUEST
 DIAGNOSTICS INCORPORATED (MI)

 
	
  

 	
 QUEST
 DIAGNOSTICS OF PENNSYLVANIA INC.

 
	
  

 	
 QUEST
 DIAGNOSTICS NICHOLS INSTITUTE, INC.

 
	
  

 	
 REGIONAL
 PATHOLOGY CONSULTANTS, LLC

 
	
  

 	
 ROCKY
 MOUNTAIN PATHOLOGY, LLC

 
	
  

 	
 SHARON G.
 DASPIT, M.D., INC.

 
	
  

 	
 SHOALS
 PATHOLOGY ASSOCIATES, INC.

 
	
  

 	
 SPECIALTY
 LABORATORIES, INC.

 
	
  

 	
 STRIGEN,
 INC.

 
	
  

 	
 TID
 ACQUISITION CORP.

 
	
  

 	
 UNILAB
 CORPORATION

 

	
  

 	
  

 	
  

 	
  

 	
  

 
	
  

 	
 By:

 	
  

 	
 /s/ William
 J. O’Shaughnessy

 
	
  

 	
  

 	

 

 
	
  

 	
  

 	
  

 	
 Name:

 	
 William J.
 O’Shaughnessy

 
	
  

 	
  

 	
  

 	
 Title:

 	
 Assistant
 General Counsel

 
	
  

 	
  

 	
  

 	
  

 	
    and
 Corporate Secretary

 

	
  

 	
  

 	
  

 
	
  

 	
 THE BANK OF
 NEW YORK MELLON,

 
	
  

 	
  

 	
 as Trustee

 
	
  

 	
  

 	
  

 
	
  

 	
 By:

 	
 /s/ Leslie Lockhart

 
	
  

 	
  

 	

 

 
	
  

 	
  

 	
 Name: Leslie Lockhart

 
	
  

 	
  

 	
 Title: Senior Associate

 

EXHIBIT A 

Form of 3.200% Senior Note due 2016

                    [The following legends apply only if the Note is a
Global Note: 

                    THIS
NOTE IS A GLOBAL NOTE WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED
TO AND IS REGISTERED IN THE NAME OF A DEPOSITORY OR A NOMINEE THEREOF. THIS
NOTE MAY NOT BE EXCHANGED IN WHOLE OR IN PART FOR A NOTE REGISTERED, AND NO
TRANSFER OF THIS NOTE IN WHOLE OR IN PART MAY BE REGISTERED, IN THE NAME OF ANY
PERSON OTHER THAN SUCH DEPOSITORY OR ITS NOMINEE EXCEPT IN THE LIMITED
CIRCUMSTANCES DESCRIBED IN THE INDENTURE. 

                    UNLESS
THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY
TRUST COMPANY TO THE ISSUER OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE
OR PAYMENT AND SUCH CERTIFICATE ISSUED IN EXCHANGE FOR THIS CERTIFICATE IS
REGISTERED IN THE NAME OF CEDE & CO., OR SUCH OTHER NAME AS REQUESTED BY AN
AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY, ANY TRANSFER, PLEDGE OR OTHER USE
HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL, SINCE THE
REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN.]

A-1

QUEST DIAGNOSTICS INCORPORATED

3.200% Senior Note due 2016

Unconditionally guaranteed as to payment of

principal of and interest by

the Subsidiary Guarantors

	
  

 	
  

 
	
 No. 0 (Specimen)

 	
 $300,000,000 

 

CUSIP: 74834L AR1 

                    Quest
Diagnostics Incorporated, a Delaware corporation (herein called the “Company,”
which term includes any successor Person under the Indenture hereinafter
referred to), for value received, hereby promises to pay to Cede & Co., or
registered assigns, the principal sum of $300,000,000 on April 1, 2016 (the “Stated Maturity”) (except to the
extent redeemed or repaid prior to the Stated Maturity) and to pay interest
thereon from March 24, 2011 or from the most recent Interest Payment Date to
which interest has been paid or duly provided for semi-annually at the rate of
3.200% per annum, on April 1 and October 1, commencing with October 1, 2011, on
the Stated Maturity and on any Redemption Date (each such date, an “Interest
Payment Date”) until the principal hereof is paid or made available for
payment. 

                    Payment
of Interest. The interest so payable, and punctually paid or made available
for payment, on any Interest Payment Date, will, as provided in the Indenture,
be paid, in immediately available funds, to the Person in whose name this Note
(or one or more Predecessor Securities) is registered at the close of business
on March 15 or September 15 (whether or not a Business Day, as defined in the
Indenture), as the case may be, next preceding such Interest Payment Date (the
“Regular Record Date”). Any such interest not punctually paid or duly provided
for (“Defaulted Interest”) will forthwith cease to be payable to the Holder on
such Regular Record Date, and such Defaulted Interest, may be paid to the
Person in whose name this Note (or one or more Predecessor Securities) is
registered at the close of business on a special record date (the “Special Record
Date”) for the payment of such Defaulted Interest to be fixed by the Trustee,
notice whereof shall be given to Holders of Notes not less than ten days prior
to such Special Record Date, or may be paid at any time in any other lawful
manner not inconsistent with requirements of any securities exchange on which
the Notes may be listed, and upon such notice as may be required by such
exchange, all as more fully provided in said Indenture. 

                    Place
of Payment. Payment of interest on this Note will be made at the Corporate
Trust Office of the Trustee or such other office or agency of the Company as
may be designated for such purpose, in such coin or currency of the United
States of America as at the time of payment is legal tender for payment of
public and private debts; provided, however, that each installment of
interest and payment of principal on this Notes may at the Company’s option be
paid in immediately available funds by transfer to an account maintained by the
payee located in the United States. Payment of the principal of this Note on
the Stated Maturity will be made against presentation of this Note at the
office or agency of the Company maintained for that purpose in the Borough of
Manhattan, The City of New York, in such coin or currency of the 

A-2

United States
of America as at the time of payment is legal tender for the payment of public
and private debts. 

                    Time
of Payment. In any case where any Interest Payment Date, Redemption Date,
Stated Maturity shall not be a Business Day at any Place of Payment, then
(notwithstanding any other provision of the Indenture or this Note), payment of
principal or interest, if any, need not be made at such Place of Payment on
such date, but may be made on the next succeeding Business Day at such Place of
Payment with the same force and effect as if made on the Interest Payment Date,
Redemption Date, or at Stated Maturity; provided that no interest shall accrue
on the amount so payable for the period from and after such Interest Payment
Date, Redemption Date, Repayment Date, or Stated Maturity, as the case may be.  

                    Legends.
The statements set forth in the restrictive legends above are an integral part
of the terms of this Note and by acceptance hereof each Holder of this Note
agrees to be subject to and bound by the terms and provisions set forth in such
legend. 

                    General.
This Note is one of a duly authorized issue of securities (herein called the
“Securities”) of the Company, issued and to be issued in one or more series
under an indenture, dated as of June 27, 2001 (the “Base Indenture”), between
the Company and The Bank of New York, Trustee (herein called the “Trustee”,
which term includes any successor trustee under the Indenture with respect to a
series of which this Note is a part), to which Base Indenture and all
indentures supplemental thereto, including the supplemental indenture dated
March 24, 2011 (the “Supplemental Indenture”), reference is hereby made for a
statement of the respective rights, limitations of rights, duties and
immunities thereunder of the Company, the Trustee and the Holders of the
Securities, and of the terms upon which the Securities are, and are to be,
authenticated and delivered. This Note is one of a duly authorized series of
Securities designated as “3.200% Senior Notes due 2016” (collectively, the
“Notes”), initially limited in aggregate principal amount to $300,000,000. 

                    Further
Issuance. The Company may from time to time, without the consent of the
Holders of Notes of this series, issue additional Notes (the “Additional
Notes”) of this series having the same ranking and the same interest rate,
maturity and other terms as the Notes of this series. Any Additional Notes of
this series and the Notes of this series will constitute a single series under
the Indenture and all references to the Notes of this series shall include the
Additional Notes unless the context otherwise requires. 

                    [The following paragraph applies only if the Note is a
Global Note: 

                    Book-Entry.
This Note is a Global Note representing $300,000,000 of the Notes. This Note is
a “book entry” Note and is being registered in the name of Cede & Co. as
nominee of The Depository Trust Company (the “Depository “), a clearing agency.
Subject to the terms of the Indenture, this Note will be held by a clearing
agency or its nominee, and beneficial interest will be held by beneficial
owners through the book-entry facilities of such clearing agency or its nominee
in minimum denominations of $2,000 and integral multiples of $1,000 in excess
thereof. As long as this Note is registered in the name of the Depository or
its nominee, the Trustee will make payments of principal and interest on this Note
by wire transfer of immediately available funds to the Depository or its
nominee. Notwithstanding the above, the 

A-3

final payment
on this Note will be made after due notice by the Trustee of the pendency of
such payment and only upon presentation and surrender of this Note at its
Corporate Trust Office or such other offices or agencies appointed by the
Trustee for that purpose and such other locations provided in the Indenture.] 

                    Guarantees.
This Note is entitled to the benefits of the Subsidiary Guarantees by each of
the Subsidiary Guarantors of the due and punctual payment and performance of
the Guarantor Obligations made in favor of the Trustee for the benefit of the
Holder of this Note. Reference is hereby made to Article Sixteen of the
Indenture for a statement of the respective rights, limitations of rights,
duties and obligations under the Guarantees of each of the Guarantors. 

                    Events
of Default. If an Event of Default with respect to the Notes shall have occurred
and be continuing, the principal of the Notes of this series may be declared
due and payable in the manner and with the effect provided in the Indenture. 

                    Optional
Redemption. The Notes of this series are not subject to any sinking fund.
The Notes of this series will be redeemable at any time, at the option of the
Company, in whole or from time to time in part, upon not less than 30 nor more
than 60 days’ prior notice, on any date prior to their maturity at a Redemption
Price, calculated pursuant to the Indenture, together with accrued interest
thereon, if any, to the Redemption Date (subject to the rights of holders of
record on the Regular Record Date that is prior to the Redemption Date to
receive interest on the relevant Interest Payment Date). In the case of any
partial redemption, selection of the Notes of this series for redemption will
be made by the Trustee by such methods, as the Trustee in its sole discretion
shall deem fair and appropriate. If any Note is to be redeemed in part only,
the notice of redemption relating to such Note shall state the portion of the
principal amount thereof to be redeemed. A new Note in principal amount equal
to the unredeemed portion thereof will be issued in the name of the Holder
thereof upon cancellation of this Note. 

                    Redemption
upon a Change of Control Triggering Event. Upon the occurrence of a Change
of Control Triggering Event, the Company shall be required to make an offer to
repurchase the Notes on the terms set forth in the Indenture. 

                    Defeasance
and Covenant Defeasance. The Indenture contains provisions for defeasance
at any time of (a) the entire indebtedness of the Company on this Note and (b)
certain restrictive covenants and the related Defaults and Events of Default,
upon compliance by the Company with certain conditions set forth therein, which
provisions apply to this Note. 

                    Modification
and Waivers; Obligations of the Company Absolute. The Indenture permits,
with certain exceptions as therein provided, the amendment thereof and the
modification of the rights and obligations of the Company and the rights of the
Holders of the Securities of each series. Such amendment may be effected under
the Indenture at any time by the Company, the Subsidiary Guarantors and the
Trustee with the consent of the Holders of not less than a majority in
aggregate principal amount of the Outstanding Notes of each series affected
thereby. The Indenture also contains provisions permitting the Holders of not
less than a majority in aggregate principal amount of the Securities at the
time Outstanding, on behalf of the Holders of all Outstanding Securities, to
waive compliance by the Company with certain provisions of the 

A-4

Indenture.
Furthermore, provisions in the Indenture permit the Holders of not less than a
majority in aggregate principal amount of the Outstanding Securities of
individual series to waive on behalf of all of the Holders of Securities of
such individual series certain past defaults under the Indenture and their
consequences. Any such consent or waiver shall be conclusive and binding upon
the Holder of this Note and upon all future Holders of this Note and of any
Note issued upon the registration of transfer hereof or in exchange hereof or
in lieu hereof, whether or not notation of such consent or waiver is made upon
this Note. 

                    No
reference herein to the Indenture and no provision of this Note or of the
Indenture shall alter or impair the obligation of the Company, which is
absolute and unconditional, to pay the principal of and interest on this Note
at the time, place, and rate, and in the coin or currency, herein prescribed. 

                    Limitation
on Suits. As set forth in, and subject to, the provisions of the Indenture,
no Holder of any Note of this series will have any right to institute any
proceeding with respect to the Indenture or for any remedy thereunder, unless
such Holder shall have previously given to the Trustee written notice of a continuing
Event of Default with respect to this series, the Holders of not less than 25%
in principal amount of the Outstanding Notes of this series shall have made
written request, and offered reasonable indemnity, to the Trustee to institute
such proceedings as trustee, and the Trustee shall not have received from the
Holders of a majority in principal amount of the Outstanding Notes of this
series a direction inconsistent with such request and shall have failed to
institute such proceeding within 60 days; provided,
however, that such limitations do
not apply to a suit instituted by the Holder hereof for the enforcement of
payment of the principal of or interest on this Note on or after the respective
due dates expressed herein. 

                    Authorized
Denominations. The Notes of this series are issuable only in registered
form without coupons in denominations of $2,000 or any integral multiple of
$1,000 in excess thereof. 

                    Registration
of Transfer or Exchange. As provided in the Indenture and subject to
certain limitations herein and therein set forth, the transfer of this Note is
registrable in the Security Register upon surrender of this Note for
registration of transfer at the office or agency of the Company in any place
where the principal of and interest on this Note are payable, duly endorsed by,
or accompanied by a written instrument of transfer in form satisfactory to the
Company and the Security Registrar duly executed by, the Holder hereof or his
attorney duly authorized in writing, and thereupon one or more new Notes, of
authorized denominations and for the same aggregate principal amount, will be
issued to the designated transferee or transferees. 

                    As
provided in the Indenture and subject to certain limitations herein and therein
set forth, the Notes are exchangeable for a like aggregate principal amount of
Notes of different authorized denominations, as requested by the Holders
surrendering the same. 

                    [The following paragraph applies only if the Note is a
Global Note:

A-5

                    This
Note is a Global Security. If the Depository is at any time unwilling,
unable or ineligible to continue as depository and a successor depository is
not appointed by the Company within 90 days or an Event of Default under the
Indenture has occurred and is continuing, the Company will issue Securities in
certificated form in exchange for each Global Security. In addition, the
Company may at any time determine not to have Securities represented by a
Global Security and, in such event, will issue Securities in certificated form
in exchange in whole for the Global Security representing such Security. In any
such instance, an owner of a beneficial interest in a Global Security will be
entitled to physical delivery in certificated form of Securities equal in
principal amount to such beneficial interest and to have such Securities
registered in its name. Securities so issued in certificated form will be
issued in denominations of $2,000 or any amount in excess thereof which is an
integral multiple of $1,000 and will be issued in registered form only, without
coupons. 

                    No
service charge shall be made for any such registration of transfer or exchange,
but the Company may require payment of a sum sufficient to cover any tax or
other governmental charge payable in connection therewith. 

                    Prior
to due presentment of this Note for registration of transfer, the Company, the
Trustee and any agent of the Company or the Trustee may treat the Holder as the
owner hereof for all purposes, whether or not this Note be overdue, and neither
the Company, the Trustee nor any such agent shall be affected by notice to the
contrary.] 

                    Defined
Terms. All terms used in this Note, which are defined in the Indenture and
are not otherwise defined herein, shall have the meanings assigned to them in
the Indenture. 

                    Governing Law. This Note shall be governed
by and construed in accordance with the law of the State of New York. 

                    Unless
the certificate of authentication hereon has been executed by the Trustee by
manual signature, this Note shall not be entitled to any benefit under the
Indenture or be valid or obligatory for any purpose. 

A-6

                    IN
WITNESS WHEREOF, the Company has caused this instrument to be duly executed. 

Dated: March
24, 2011 

	
  

 	
  

 	
  

 
	
  

 	
 QUEST
 DIAGNOSTICS INCORPORATED

 
	
  

 	
  

 	
  

 
	
  

 	
 By:

 	
  

 
	
  

 	
  

 	

 

 
	
  

 	
 Name: Robert
 O’Keef

 
	
 Attest:

 	
 Title:   Vice
 President and Treasurer

 

	
  

 	
  

 	
  

 
	
 By:

 	
  

 	
  

 
	
  

 	

 

 	
  

 
	
 Name:
 William J. O’Shaughnessy, Jr.

 
	
 Title:   Assistant
 General Counsel and Corporate Secretary

 

A-7

TRUSTEE’S CERTIFICATE OF AUTHENTICATION

                    This
is one of the Notes of the series designated and referred to in the
within-mentioned Indenture, as such is supplemented by the within-mentioned
Fourteenth Supplemental Indenture. 

	
  

 	
  

 	
  

 
	
  

 	
 THE BANK OF
 NEW YORK MELLON

 
	
  

 	
 as Trustee

 
	
  

 	
  

 	
  

 
	
  

 	
 By:

 	
  

 
	
  

 	
  

 	

 

 
	
  

 	
  

 	
 Name:

 
	
  

 	
  

 	
 Title:

 
	
  

 	
  

 	
  

 
	
 Dated: March
 24, 2011

 	
  

 	
  

 

A-8

GUARANTEE OF THE SUBSIDIARY GUARANTORS

                    FOR
VALUE RECEIVED, each of the Subsidiary Guarantors (as such term is defined in
the Indenture, as amended by the First Supplemental Indenture, the Second
Supplemental Indenture, the Third Supplemental Indenture, the Fourth
Supplemental Indenture, the Fifth Supplemental Indenture, the Sixth
Supplemental Indenture, the Seventh Supplemental Indenture, the Eighth
Supplemental Indenture, the Ninth Supplemental Indenture, the Tenth
Supplemental Indenture, the Eleventh Supplemental Indenture, the Twelfth
Supplemental Indenture, the Thirteenth Supplemental Indenture and the
Fourteenth Supplemental Indenture), hereby, jointly and severally,
unconditionally guarantees to the Holder of the Note upon which this Subsidiary
Guarantee is endorsed (the “Note”) and to the Trustee on behalf of the Holder,
the prompt payment of the principal of (and premium, if any, on) and interest
(including, in case of default, interest on principal and, to the extent
permitted by applicable law, on overdue interest and including any additional
interest required to be paid according to the terms of the Notes) on the Note,
when due (whether at Stated Maturity, upon Redemption, upon acceleration, upon
tender for repayment at the option of the Company), according to the terms
hereof and the terms of the Indenture (the “Guarantor Obligations”). This
Guarantee is a guarantee of payment and not of collection and is a continuing
guarantee and shall apply to all Guarantor Obligations whenever arising. 

                    Obligations
Unconditional and Absolute. The obligations of the Subsidiary Guarantors
hereunder are absolute and unconditional irrespective of the value,
genuineness, validity, regularity or enforceability of the Indenture or this
Note, to the fullest extent permitted by applicable law, irrespective of any
circumstance whatsoever which might otherwise constitute a legal or equitable
discharge or defense of a surety or guarantor. Each of the Subsidiary
Guarantors agrees that this Guarantee may be enforced by the Holder of this
Note without the necessity at any time of proceeding against the Company or any
other Person (including a co-guarantor) or to pursue any other remedy or
enforce any other right. Each of the Subsidiary Guarantors further agrees that
nothing contained herein shall prevent the Holder of this Note from suing on
this Note or the Indenture or from exercising any other rights available under
this Note and the Indenture, and the exercise of any of the aforesaid rights
and shall not constitute a discharge of any Subsidiary Guarantor’s obligations
hereunder and under the Indenture; it being the purpose and the intent of each
Subsidiary Guarantor that its obligations under this Note and under the
Indenture shall be absolute, independent and unconditional under any and all
circumstances. Neither any Subsidiary Guarantor’s obligations under this
Guarantee nor any remedy for the enforcement thereof shall be impaired,
modified, changed or released in any manner whatsoever by an impairment,
modification, change, release or limitation of the liability of the Company or
by reason of the bankruptcy or insolvency of the Company. Each Subsidiary
Guarantor waives any and all notice of the creation, renewal, extension or
accrual of any of the Guarantor Obligations or acceptance of this Guarantee.
The Guarantor Obligations, and any of them, shall conclusively be deemed to
have been created, contracted or incurred, or renewed, extended, amended or
waived, in reliance upon this Guarantee. 

                    Subrogation.
Each of the Subsidiary Guarantors shall be subrogated to all rights of the
Holder of the Note against the Company in respect of any amounts paid by such
Subsidiary Guarantor on account of the Note or the Indenture; provided, however,
that such Subsidiary Guarantor shall not be entitled to enforce or to receive
any payments arising out of, or 

A-9

based upon,
such right of subrogation until the principal of (or premium, if any, on) and
interest on all Notes of this series shall have been indefeasibly paid in full.

                    Modifications.
Each Subsidiary Guarantor agrees that (a) the time or place of payment of the
Guarantor Obligations may be changed or extended, in whole or in part, to a
time certain or otherwise, and may be renewed or accelerated, in whole or in
part; (b) the Company and any other party liable for payment under the
Indenture or under the Note may be granted indulgences generally; (c) any of
the provisions of this Note or the Indenture may be modified, amended or
waived; and (d) any party (including any Subsidiary Guarantor) liable for the
payment under this Note or under the Indenture may be granted indulgences or be
released; all without notice to or further assent by such Subsidiary Guarantor,
which shall remain bound thereon, notwithstanding any such exchange,
compromise, surrender, extension, renewal, acceleration, modification,
indulgence or release. 

                    Waiver
of Rights. Each of the Subsidiary Guarantors hereby waives to the fullest
extent permitted by law: (a) notice of acceptance of this Guarantee by the
Holder of this Note; (b) presentment and demand for payment or performance of
any of the Guarantor Obligations; (c) protest and notice of dishonor or default
with respect to the Guarantor Obligations; (d) all other notices to which such
Subsidiary Guarantor might otherwise be entitled. 

                    Reinstatement.
The obligations of the Subsidiary Guarantors under this Note and under Article
Sixteen shall be automatically reinstated if and to the extent that for any
reason any payment by or on behalf of any Person in respect of the Guarantor
Obligations is rescinded or must otherwise be restored by any Holder of the
Notes of this series, whether as a result of any proceedings in bankruptcy or
reorganization or otherwise. 

                    Remedies.
Each of the Subsidiary Guarantors further agrees, to the fullest extent that it
may lawfully do so, that as between each such Subsidiary Guarantor, on the one
hand, and the Holder and the Trustee, on the other hand, the maturity of the
obligations guaranteed hereby may be accelerated as provided in Article Five of
the Indenture for the purposes of this guarantee, notwithstanding any stay,
injunction or other prohibition extant under any applicable bankruptcy law
preventing such acceleration in respect of the obligations guaranteed hereby. 

                    Rights
of Contribution. The Subsidiary Guarantors, in connection with payments
made hereunder, shall have contribution rights against the other Subsidiary
Guarantors as permitted under applicable law. Such contribution rights shall be
subordinate and subject in right of payment to the obligations of the
Subsidiary Guarantors under this Note and no Subsidiary Guarantor shall
exercise such rights of contribution until all Guarantor Obligations have been
paid in full. 

                    Limitation
of Guaranty. Notwithstanding any provision to the contrary contained herein
or in the Indenture, to the extent the obligations of any Subsidiary Guarantor
shall be adjudicated to be invalid or unenforceable for any reason (including,
without limitation, because of any applicable state or federal law relating to
fraudulent conveyances or transfers) then the obligations of the Subsidiary
Guarantors hereunder shall be limited to the maximum amount that is permissible
under applicable law (whether federal or state or otherwise and including,
without limitation, the Bankruptcy Code). 

A-10

                    Release
of Guarantors. Each of the Subsidiary Guarantors hereby covenants that its
Subsidiary Guarantee will not be discharged except by complete performance of
its obligations contained in the Note, this Subsidiary Guarantee and pursuant
to the Indenture; provided, however, that if (a) an Subsidiary
Guarantor does not guarantee any Indebtedness of the Company the amount of
which, when added together with any other outstanding Indebtedness of the
Company guaranteed by its Subsidiaries that are not Subsidiary Guarantors,
would exceed $50 million in the aggregate, excluding the Notes of this series,
and all outstanding Indebtedness of such Subsidiary Guarantor would have been
permitted to be incurred pursuant to Section 1011 of the Indenture measured at
the time of the release and discharge as described in this paragraph, (b) the
Notes of this series are defeased and discharged pursuant to Article Fourteen
of the Indenture, or (c) all or substantially all of the assets of such
Subsidiary Guarantor or all of the capital stock of such Subsidiary Guarantor
is sold (including by issuance, merger, consolidation or otherwise) by the
Company or any of its Subsidiaries, then in each case of (a), (b) or (c) above,
such Subsidiary Guarantor or the corporation acquiring such assets (in the event
of a sale or other disposition of all or substantially all of the assets or
capital stock of such Subsidiary Guarantor) shall be automatically and without
any further action on the part of any party to the Indenture, and upon notice
to the Trustee, be fully released and discharged from all its liabilities and
obligations under or in respect of the Indenture and this Subsidiary Guarantee
of the Note, and promptly upon the request of the Company and at the expense of
the Company, the Trustee shall execute such documents and take such other
action as is reasonably requested by the Company to evidence the release and
discharge of such Guarantor from all such liabilities and obligations and
shall, if applicable, certify to the Company that such Subsidiary Guarantor has
no liabilities or obligations resulting from a demand on such Subsidiary
Guarantor’s Guarantee. 

                    Defined
Terms. All terms used in this Note, which are defined in the Indenture and
are not otherwise defined herein, shall have the meanings assigned to them in
the Indenture.

                    Governing
Law. This Subsidiary Guarantee shall be governed by and construed in
accordance with the law of the State of New York. 

                    Subject
to the next following paragraph, each Subsidiary Guarantor hereby certifies and
warrants that all acts, conditions and things required to be done and performed
and to have happened precedent to the creation and issuance of this Subsidiary
Guarantee and to constitute the same valid obligation of each Subsidiary
Guarantor have been done and performed and have happened in due compliance with
all applicable laws. 

(Remainder of page intentionally left blank.)

A-11

This Subsidiary Guarantee shall not be valid
or become obligatory for any purpose until the certificate of authentication on
the Note upon which this Subsidiary Guarantee is endorsed has been signed by the Trustee under the Indenture referred to in this Note.

	
  

 	
  

 
	
 Dated: March
 24, 2011

 	
  

 
	
  

 	
  

 
	
  

 	
 AMERICAN
 MEDICAL LABORATORIES,

 
	
  

 	
 INCORPORATED

 
	
  

 	
 AMERIPATH,
 INC.

 
	
  

 	
 AMERIPATH
 CONSOLIDATED LABS, INC.

 
	
  

 	
 AMERIPATH
 FLORIDA, LLC

 
	
  

 	
 AMERIPATH
 GROUP HOLDINGS, INC.

 
	
  

 	
 AMERIPATH
 HOLDINGS, INC.

 
	
  

 	
 AMERIPATH
 HOSPITAL SERVICES FLORIDA, LLC

 
	
  

 	
 AMERIPATH
 INDIANA, LLC

 
	
  

 	
 AMERIPATH
 INTERMEDIATE HOLDINGS, INC.

 
	
  

 	
 AMERIPATH
 KENTUCKY, INC.

 
	
  

 	
 AMERIPATH
 MARKETING USA, INC.

 
	
  

 	
 AMERIPATH
 MICHIGAN, INC.

 
	
  

 	
 AMERIPATH
 MISSISSIPPI, INC.

 
	
  

 	
 AMERIPATH
 NEW YORK, LLC

 
	
  

 	
 AMERIPATH
 NORTH CAROLINA, INC.

 
	
  

 	
 AMERIPATH
 OHIO, INC.

 
	
  

 	
 AMERIPATH
 PENNSYLVANIA, LLC

 
	
  

 	
 AMERIPATH
 PHILADELPHIA, INC.

 
	
  

 	
 AMERIPATH
 SC, INC.

 
	
  

 	
 AMERIPATH
 TEXAS, L.P.

 
	
  

 	
 AMERIPATH
 YOUNGSTOWN LABS, INC.

 
	
  

 	
 AMERIPATH
 WISCONSIN, LLC

 
	
  

 	
 AMERIPATH,
 LLC

 
	
  

 	
 API NO. 2,
 LLC

 
	
  

 	
 ANATOMIC
 PATHOLOGY SERVICES, INC.

 
	
  

 	
 ARIZONA
 PATHOLOGY GROUP, INC.

 
	
  

 	
 APL
 PROPERTIES LIMITED LIABILITY COMPANY

 
	
  

 	
 CENTRAL
 PLAINS HOLDINGS, INC.

 
	
  

 	
 DERMATOPATHOLOGY
 SERVICES, INC.

 
	
  

 	
 DIAGNOSTIC
 PATHOLOGY MANAGEMENT SERVICES, LLC

 
	
  

 	
 DIAGNOSTIC
 REFERENCE SERVICES, INC.

 
	
  

 	
 DPD
 HOLDINGS, INC.

 
	
  

 	
 ENTERIX INC.

 
	
  

 	
 EXAMONE
 WORLD WIDE, INC.

 
	
  

 	
 EXAMONE
 WORLD WIDE OF NJ, INC.

 
	
  

 	
 FOCUS TECHNOLOGIES
 HOLDING COMPANY

 
	
  

 	
 FOCUS
 DIAGNOSTICS, INC.

 
	
  

 	
 HEMOCUE,
 INC.

 

A-12

	
  

 	
  

 
	
  

 	
 KAILASH B.
 SHARMA, M.D., INC.

 
	
  

 	
 LABONE, INC.

 
	
  

 	
 LABONE OF
 OHIO, INC.

 
	
  

 	
 MEDPLUS,
 INC.

 
	
  

 	
 METWEST INC.

 
	
  

 	
 NICHOLS
 INSTITUTE DIAGNOSTICS

 
	
  

 	
 OSBORN GROUP
 INC.

 
	
  

 	
 OCMULGEE
 MEDICAL PATHOLOGY ASSOCIATION, INC.

 
	
  

 	
 O’QUINN
 MEDICAL PATHOLOGY ASSOCIATION, LLC

 
	
  

 	
 PATHOLOGY
 BUILDING PARTNERSHIP

 
	
  

 	
 PCA OF
 DENVER, INC.

 
	
  

 	
 PCA OF
 NASHVILLE, INC.

 
	
  

 	
 PETER G.
 KLACSMANN M.D., INC.

 
	
  

 	
 QUEST
 DIAGNOSTICS HOLDINGS INCORPORATED

 
	
  

 	
 QUEST
 DIAGNOSTICS CLINICAL LABORATORIES, INC.

 
	
  

 	
 QUEST
 DIAGNOSTICS NICHOLS INSTITUTE

 
	
  

 	
 QUEST
 DIAGNOSTICS FINANCE INCORPORATED

 
	
  

 	
 QUEST
 DIAGNOSTICS INVESTMENTS INCORPORATED

 
	
  

 	
 QUEST
 DIAGNOSTICS INCORPORATED (NV)

 
	
  

 	
 QUEST
 DIAGNOSTICS INCORPORATED (MD)

 
	
  

 	
 QUEST
 DIAGNOSTICS LLC (IL)

 
	
  

 	
 QUEST
 DIAGNOSTICS LLC (CT)

 
	
  

 	
 QUEST
 DIAGNOSTICS LLC (MA)

 
	
  

 	
 QUEST
 DIAGNOSTICS INCORPORATED (MI)

 
	
  

 	
 QUEST
 DIAGNOSTICS OF PENNSYLVANIA INC.

 
	
  

 	
 QUEST
 DIAGNOSTICS NICHOLS INSTITUTE, INC.

 
	
  

 	
 REGIONAL
 PATHOLOGY CONSULTANTS, LLC

 
	
  

 	
 ROCKY
 MOUNTAIN PATHOLOGY, LLC

 
	
  

 	
 SHARON G.
 DASPIT, M.D., INC.

 
	
  

 	
 SHOALS
 PATHOLOGY ASSOCIATES, INC.

 
	
  

 	
 SPECIALTY
 LABORATORIES, INC.

 
	
  

 	
 STRIGEN,
 INC.

 
	
  

 	
 TID
 ACQUISITION CORP.

 
	
  

 	
 UNILAB
 CORPORATION

 

A-13

	
  

 	
  

 	
  

 	
  

 	
  

 
	
  

 	
  

 	
 By:  

 	
  

 	
  

 
	
  

 	
  

 	
  

 	
 

 	

 

 
	
  

 	
  

 	
  

 	
 Name: 

 	
 William J.
 O’Shaughnessy

 
	
  

 	
  

 	
  

 	
 Title:

 	
 Assistant
 General Counsel

 
	
  

 	
  

 	
  

 	
  

 	
 and
 Corporate Secretary

 

Attest:

	
  

 	
  

 
	
 By:

 	
  

 
	
  

 	

 

 
	
  

 	
 Name:

 
	
  

 	
 Title:

 

A-14

EXHIBIT B 

Form of 4.700% Senior Note due 2021

                    [The
following legends apply only if the Note is a Global Note:

                    THIS
NOTE IS A GLOBAL NOTE WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED
TO AND IS REGISTERED IN THE NAME OF A DEPOSITORY OR A NOMINEE THEREOF. THIS
NOTE MAY NOT BE EXCHANGED IN WHOLE OR IN PART FOR A NOTE REGISTERED, AND NO
TRANSFER OF THIS NOTE IN WHOLE OR IN PART MAY BE REGISTERED, IN THE NAME OF ANY
PERSON OTHER THAN SUCH DEPOSITORY OR ITS NOMINEE EXCEPT IN THE LIMITED
CIRCUMSTANCES DESCRIBED IN THE INDENTURE. 

                    UNLESS
THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY
TRUST COMPANY TO THE ISSUER OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE
OR PAYMENT AND SUCH CERTIFICATE ISSUED IN EXCHANGE FOR THIS CERTIFICATE IS
REGISTERED IN THE NAME OF CEDE & CO., OR SUCH OTHER NAME AS REQUESTED BY AN
AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY, ANY TRANSFER, PLEDGE OR OTHER USE
HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL, SINCE THE
REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN.]

B-1

QUEST DIAGNOSTICS INCORPORATED

4.700% Senior Note due 2021

Unconditionally guaranteed as to payment of 

principal of and interest by 

the Subsidiary Guarantors

	
  

 	
  

 
	
 No. 0 (Specimen)

 	
 $550,000,000

 

CUSIP: 74834L AS9

                    Quest
Diagnostics Incorporated, a Delaware corporation (herein called the “Company,”
which term includes any successor Person under the Indenture hereinafter
referred to), for value received, hereby promises to pay to Cede & Co., or
registered assigns, the principal sum of $550,000,000 on April 1, 2021 (the “Stated Maturity”) (except to the
extent redeemed or repaid prior to the Stated Maturity) and to pay interest
thereon from March 24, 2011 or from the most recent Interest Payment Date to
which interest has been paid or duly provided for semi-annually at the rate of
4.700% per annum, on April 1 and October 1, commencing with October 1, 2011, on
the Stated Maturity and on any Redemption Date (each such date, an “Interest
Payment Date”) until the principal hereof is paid or made available for
payment. 

                    Payment
of Interest. The interest so payable, and punctually paid or made available
for payment, on any Interest Payment Date, will, as provided in the Indenture,
be paid, in immediately available funds, to the Person in whose name this Note
(or one or more Predecessor Securities) is registered at the close of business
on March 15 or September 15 (whether or not a Business Day, as defined in the
Indenture), as the case may be, next preceding such Interest Payment Date (the
“Regular Record Date”). Any such interest not punctually paid or duly provided
for (“Defaulted Interest”) will forthwith cease to be payable to the Holder on
such Regular Record Date, and such Defaulted Interest, may be paid to the
Person in whose name this Note (or one or more Predecessor Securities) is
registered at the close of business on a special record date (the “Special
Record Date”) for the payment of such Defaulted Interest to be fixed by the
Trustee, notice whereof shall be given to Holders of Notes not less than ten
days prior to such Special Record Date, or may be paid at any time in any other
lawful manner not inconsistent with requirements of any securities exchange on
which the Notes may be listed, and upon such notice as may be required by such
exchange, all as more fully provided in said Indenture. 

                    Place
of Payment. Payment of interest on this Note will be made at the Corporate
Trust Office of the Trustee or such other office or agency of the Company as
may be designated for such purpose, in such coin or currency of the United
States of America as at the time of payment is legal tender for payment of
public and private debts; provided, however, that each installment of
interest and payment of principal on this Notes may at the Company’s option be
paid in immediately available funds by transfer to an account maintained by the
payee located in the United States. Payment of the principal of this Note on
the Stated Maturity will be made against presentation of this Note at the
office or agency of the Company maintained for that purpose in the Borough of
Manhattan, The City of New York, in such coin or currency of the United States
of America as at the time of payment is legal tender for the payment of public
and private debts. 

B-2

                    Time
of Payment. In any case where any Interest Payment Date, Redemption Date,
Stated Maturity shall not be a Business Day at any Place of Payment, then
(notwithstanding any other provision of the Indenture or this Note), payment of
principal or interest, if any, need not be made at such Place of Payment on
such date, but may be made on the next succeeding Business Day at such Place of
Payment with the same force and effect as if made on the Interest Payment Date,
Redemption Date, or at Stated Maturity; provided that no interest shall accrue
on the amount so payable for the period from and after such Interest Payment
Date, Redemption Date, Repayment Date, or Stated Maturity, as the case may be.  

                    Legends.
The statements set forth in the restrictive legends above are an integral part
of the terms of this Note and by acceptance hereof each Holder of this Note
agrees to be subject to and bound by the terms and provisions set forth in such
legend. 

                    General.
This Note is one of a duly authorized issue of securities (herein called the
“Securities”) of the Company, issued and to be issued in one or more series
under an indenture, dated as of June 27, 2001 (the “Base Indenture”), between
the Company and The Bank of New York, Trustee (herein called the “Trustee”, which
term includes any successor trustee under the Indenture with respect to a
series of which this Note is a part), to which Base Indenture and all
indentures supplemental thereto, including the supplemental indenture dated
March 24, 2011 (the “Supplemental Indenture”), reference is hereby made for a
statement of the respective rights, limitations of rights, duties and
immunities thereunder of the Company, the Trustee and the Holders of the
Securities, and of the terms upon which the Securities are, and are to be,
authenticated and delivered. This Note is one of a duly authorized series of
Securities designated as “4.700% Senior Notes due 2021” (collectively, the
“Notes”), initially limited in aggregate principal amount to $550,000,000. 

                    Further
Issuance. The Company may from time to time, without the consent of the
Holders of Notes of this series, issue additional Notes (the “Additional
Notes”) of this series having the same ranking and the same interest rate,
maturity and other terms as the Notes of this series. Any Additional Notes of
this series and the Notes of this series will constitute a single series under
the Indenture and all references to the Notes of this series shall include the
Additional Notes unless the context otherwise requires. 

                    [The following paragraph applies only if the Note is a
Global Note:

                    Book-Entry.
This Note is a Global Note representing $550,000,000 of the Notes. This Note is
a “book entry” Note and is being registered in the name of Cede & Co. as
nominee of The Depository Trust Company (the “Depository “), a clearing agency.
Subject to the terms of the Indenture, this Note will be held by a clearing
agency or its nominee, and beneficial interest will be held by beneficial owners
through the book-entry facilities of such clearing agency or its nominee in
minimum denominations of $2,000 and integral multiples of $1,000 in excess
thereof. As long as this Note is registered in the name of the Depository or
its nominee, the Trustee will make payments of principal and interest on this
Note by wire transfer of immediately available funds to the Depository or its
nominee. Notwithstanding the above, the final payment on this Note will be made
after due notice by the Trustee of the pendency of such payment and only upon
presentation and surrender of this Note at its Corporate Trust Office or such
other offices or agencies appointed by the Trustee for that purpose and such
other locations provided in the Indenture.] 

B-3

                    Guarantees.
This Note is entitled to the benefits of the Subsidiary Guarantees by each of
the Subsidiary Guarantors of the due and punctual payment and performance of
the Guarantor Obligations made in favor of the Trustee for the benefit of the
Holder of this Note. Reference is hereby made to Article Sixteen of the
Indenture for a statement of the respective rights, limitations of rights,
duties and obligations under the Guarantees of each of the Guarantors. 

                    Events
of Default. If an Event of Default with respect to the Notes shall have
occurred and be continuing, the principal of the Notes of this series may be
declared due and payable in the manner and with the effect provided in the
Indenture. 

                    Optional
Redemption. The Notes of this series are not subject to any sinking fund.
The Notes of this series will be redeemable at any time, at the option of the
Company, in whole or from time to time in part, upon not less than 30 nor more
than 60 days’ prior notice, on any date prior to their maturity at a Redemption
Price, calculated pursuant to the Indenture, together with accrued interest
thereon, if any, to the Redemption Date (subject to the rights of holders of
record on the Regular Record Date that is prior to the Redemption Date to
receive interest on the relevant Interest Payment Date). In the case of any
partial redemption, selection of the Notes of this series for redemption will
be made by the Trustee by such methods, as the Trustee in its sole discretion
shall deem fair and appropriate. If any Note is to be redeemed in part only,
the notice of redemption relating to such Note shall state the portion of the
principal amount thereof to be redeemed. A new Note in principal amount equal
to the unredeemed portion thereof will be issued in the name of the Holder
thereof upon cancellation of this Note. 

                    Special
Mandatory Redemption. If the Company has failed to consummate the
acquisition of Athena Diagnostics, Inc. on or prior to October 31, 2011, or the
related Stock Purchase and Sale Agreement, dated as of February 23, 2011,
between Thermo Fisher Scientific Inc., a Delaware corporation and the Company
(the “Stock Purchase and Sale Agreement”) is terminated at any time prior
thereto, then the Company must redeem all of the Notes of this series on the
Special Mandatory Redemption Date (as defined below) at a redemption price
equal to 101% of the aggregate principal amount of the Notes, plus accrued and
unpaid interest from the date of initial issuance to, but excluding, the
Special Mandatory Redemption Date (subject to the right of holders of record on
the relevant record date to receive interest due on the relevant Interest
Payment Date). The “Special Mandatory Redemption Date” means the earlier to occur
of (1) November 15, 2011, if the acquisition of Athena Diagnostics, Inc. has
not been completed on or prior to October 31, 2011, or (2) the 30th day (or if
such day is not a Business Day, the first Business Day thereafter) following
the termination of the Stock Purchase and Sale Agreement for any reason. 

                    Redemption
upon a Change of Control Triggering Event. Upon the occurrence of a Change
of Control Triggering Event, the Company shall be required to make an offer to
repurchase the Notes on the terms set forth in the Indenture. 

                    Defeasance
and Covenant Defeasance. The Indenture contains provisions for defeasance
at any time of (a) the entire indebtedness of the Company on this Note and (b)
certain restrictive covenants and the related Defaults and Events of Default,
upon compliance by the Company with certain conditions set forth therein, which
provisions apply to this Note. 

B-4

                    Modification
and Waivers; Obligations of the Company Absolute. The Indenture permits,
with certain exceptions as therein provided, the amendment thereof and the
modification of the rights and obligations of the Company and the rights of the
Holders of the Securities of each series. Such amendment may be effected under the
Indenture at any time by the Company, the Subsidiary Guarantors and the Trustee
with the consent of the Holders of not less than a majority in aggregate
principal amount of the Outstanding Notes of each series affected thereby. The
Indenture also contains provisions permitting the Holders of not less than a
majority in aggregate principal amount of the Securities at the time
Outstanding, on behalf of the Holders of all Outstanding Securities, to waive
compliance by the Company with certain provisions of the Indenture.
Furthermore, provisions in the Indenture permit the Holders of not less than a
majority in aggregate principal amount of the Outstanding Securities of
individual series to waive on behalf of all of the Holders of Securities of
such individual series certain past defaults under the Indenture and their
consequences. Any such consent or waiver shall be conclusive and binding upon
the Holder of this Note and upon all future Holders of this Note and of any
Note issued upon the registration of transfer hereof or in exchange hereof or
in lieu hereof, whether or not notation of such consent or waiver is made upon
this Note. 

                    No
reference herein to the Indenture and no provision of this Note or of the
Indenture shall alter or impair the obligation of the Company, which is
absolute and unconditional, to pay the principal of and interest on this Note
at the time, place, and rate, and in the coin or currency, herein prescribed. 

                    Limitation
on Suits. As set forth in, and subject to, the provisions of the Indenture,
no Holder of any Note of this series will have any right to institute any
proceeding with respect to the Indenture or for any remedy thereunder, unless
such Holder shall have previously given to the Trustee written notice of a
continuing Event of Default with respect to this series, the Holders of not
less than 25% in principal amount of the Outstanding Notes of this series shall
have made written request, and offered reasonable indemnity, to the Trustee to institute
such proceedings as trustee, and the Trustee shall not have received from the
Holders of a majority in principal amount of the Outstanding Notes of this
series a direction inconsistent with such request and shall have failed to
institute such proceeding within 60 days; provided,
however, that such limitations do
not apply to a suit instituted by the Holder hereof for the enforcement of
payment of the principal of or interest on this Note on or after the respective
due dates expressed herein. 

                    Authorized
Denominations. The Notes of this series are issuable only in registered
form without coupons in denominations of $2,000 or any integral multiple of
$1,000 in excess thereof. 

                    Registration
of Transfer or Exchange. As provided in the Indenture and subject to
certain limitations herein and therein set forth, the transfer of this Note is
registrable in the Security Register upon surrender of this Note for
registration of transfer at the office or agency of the Company in any place
where the principal of and interest on this Note are payable, duly endorsed by,
or accompanied by a written instrument of transfer in form satisfactory to the
Company and the Security Registrar duly executed by, the Holder hereof or his attorney
duly authorized in writing, and thereupon one or more new Notes, of authorized
denominations and for the same aggregate principal amount, will be issued to
the designated transferee or transferees. 

B-5

                    As
provided in the Indenture and subject to certain limitations herein and therein
set forth, the Notes are exchangeable for a like aggregate principal amount of
Notes of different authorized denominations, as requested by the Holders
surrendering the same. 

                    [The following paragraph applies only if the Note is a
Global Note:

                    This
Note is a Global Security. If the Depository is at any time unwilling, unable
or ineligible to continue as depository and a successor depository is not
appointed by the Company within 90 days or an Event of Default under the
Indenture has occurred and is continuing, the Company will issue Securities in
certificated form in exchange for each Global Security. In addition, the
Company may at any time determine not to have Securities represented by a
Global Security and, in such event, will issue Securities in certificated form
in exchange in whole for the Global Security representing such Security. In any
such instance, an owner of a beneficial interest in a Global Security will be
entitled to physical delivery in certificated form of Securities equal in
principal amount to such beneficial interest and to have such Securities
registered in its name. Securities so issued in certificated form will be
issued in denominations of $2,000 or any amount in excess thereof which is an
integral multiple of $1,000 and will be issued in registered form only, without
coupons.  

                    No
service charge shall be made for any such registration of transfer or exchange,
but the Company may require payment of a sum sufficient to cover any tax or
other governmental charge payable in connection therewith. 

                    Prior
to due presentment of this Note for registration of transfer, the Company, the
Trustee and any agent of the Company or the Trustee may treat the Holder as the
owner hereof for all purposes, whether or not this Note be overdue, and neither
the Company, the Trustee nor any such agent shall be affected by notice to the
contrary.] 

                    Defined
Terms. All terms used in this Note, which are defined in the Indenture and
are not otherwise defined herein, shall have the meanings assigned to them in
the Indenture. 

                    Governing
Law. This Note shall be governed by and construed in accordance with the
law of the State of New York. 

                    Unless
the certificate of authentication hereon has been executed by the Trustee by
manual signature, this Note shall not be entitled to any benefit under the
Indenture or be valid or obligatory for any purpose. 

B-6

                    IN
WITNESS WHEREOF, the Company has caused this instrument to be duly executed. 

Dated: March
24, 2011 

	
  

 	
  

 	
  

 	
  

 	
  

 
	
  

 	
  

 	
 QUEST
 DIAGNOSTICS INCORPORATED

 
	
  

 	
  

 	
  

 
	
  

 	
  

 	
 By: 

 	
  

 
	
  

 	
  

 	
  

 	

 

 
	
  

 	
  

 	
 Name: 

 	
 Robert
 O’Keef

 
	
 Attest:

 	
  

 	
 Title: 

 	
 Vice
 President and Treasurer

 

	
  

 	
  

 	
  

 	
  

 
	
 By:

 	
  

 	
  

 
	
  

 	

 

 	
  

 
	
 Name:

 	
 William J.
 O’Shaughnessy, Jr.

 	
  

 
	
 Title:

 	
 Assistant
 General Counsel and Corporate Secretary

 	
  

 

B-7

TRUSTEE’S CERTIFICATE OF AUTHENTICATION

                    This
is one of the Notes of the series designated and referred to in the
within-mentioned Indenture, as such is supplemented by the within-mentioned
Fourteenth Supplemental Indenture. 

	
  

 	
  

 	
  

 	
  

 
	
  

 	
  

 	
 THE BANK OF
 NEW YORK MELLON

 
	
  

 	
  

 	
 as Trustee

 
	
  

 	
  

 	
  

 	
  

 
	
  

 	
  

 	
 By:

 	
  

 
	
  

 	
  

 	
  

 	

 

 
	
  

 	
  

 	
  

 	
 Name:

 
	
  

 	
  

 	
  

 	
 Title:

 
	
  

 	
  

 	
  

 	
  

 
	
 Dated:

 	
 March 24,
 2011

 	
  

 	
  

 

B-8

GUARANTEE OF THE SUBSIDIARY GUARANTORS

                    FOR
VALUE RECEIVED, each of the Subsidiary Guarantors (as such term is defined in
the Indenture, as amended by the First Supplemental Indenture, the Second
Supplemental Indenture, the Third Supplemental Indenture, the Fourth
Supplemental Indenture, the Fifth Supplemental Indenture, the Sixth
Supplemental Indenture, the Seventh Supplemental Indenture, the Eighth
Supplemental Indenture, the Ninth Supplemental Indenture, the Tenth
Supplemental Indenture, the Eleventh Supplemental Indenture, the Twelfth
Supplemental Indenture, the Thirteenth Supplemental Indenture and the
Fourteenth Supplemental Indenture), hereby, jointly and severally,
unconditionally guarantees to the Holder of the Note upon which this Subsidiary
Guarantee is endorsed (the “Note”) and to the Trustee on behalf of the Holder,
the prompt payment of the principal of (and premium, if any, on) and interest
(including, in case of default, interest on principal and, to the extent
permitted by applicable law, on overdue interest and including any additional
interest required to be paid according to the terms of the Notes) on the Note,
when due (whether at Stated Maturity, upon Redemption, upon acceleration, upon
tender for repayment at the option of the Company), according to the terms
hereof and the terms of the Indenture (the “Guarantor Obligations”). This Guarantee is a guarantee of payment and
not of collection and is a continuing guarantee and shall apply to all
Guarantor Obligations whenever arising.

                    Obligations
Unconditional and Absolute. The
obligations of the Subsidiary Guarantors hereunder are absolute and
unconditional irrespective of the value, genuineness, validity, regularity or
enforceability of the Indenture or this Note, to the fullest extent permitted
by applicable law, irrespective of any circumstance whatsoever which might
otherwise constitute a legal or equitable discharge or defense of a surety or
guarantor. Each of the Subsidiary
Guarantors agrees that this Guarantee may be enforced by the Holder of this
Note without the necessity at any time of proceeding against the Company or any
other Person (including a co-guarantor) or to pursue any other remedy or
enforce any other right. Each of the
Subsidiary Guarantors further agrees that nothing contained herein shall
prevent the Holder of this Note from suing on this Note or the Indenture or
from exercising any other rights available under this Note and the Indenture,
and the exercise of any of the aforesaid rights and shall not constitute a
discharge of any Subsidiary Guarantor’s obligations hereunder and under the
Indenture; it being the purpose and the intent of each Subsidiary Guarantor
that its obligations under this Note and under the Indenture shall be absolute, independent and unconditional
under any and all circumstances.
Neither any Subsidiary Guarantor’s obligations under this Guarantee nor
any remedy for the enforcement thereof shall be impaired, modified, changed or
released in any manner whatsoever by an impairment, modification, change,
release or limitation of the liability of the Company or by reason of the
bankruptcy or insolvency of the Company.
Each Subsidiary Guarantor waives any and all notice of the creation,
renewal, extension or accrual of any of the Guarantor Obligations or acceptance
of this Guarantee. The Guarantor
Obligations, and any of them, shall conclusively be deemed to have been
created, contracted or incurred, or renewed, extended, amended or waived, in
reliance upon this Guarantee.

                    Subrogation. Each of the Subsidiary Guarantors shall be
subrogated to all rights of the Holder of the Note against the Company in
respect of any amounts paid by such Subsidiary Guarantor on account of the Note
or the Indenture; provided, however,
that such Subsidiary Guarantor shall not be entitled to enforce or to receive
any payments arising out of, or 

B-9

based upon,
such right of subrogation until the principal of (or premium, if any, on) and
interest on all Notes of this series shall have been indefeasibly paid in full.

                    Modifications. Each Subsidiary Guarantor agrees that (a)
the time or place of payment of the Guarantor Obligations may be changed or
extended, in whole or in part, to a time certain or otherwise, and may be
renewed or accelerated, in whole or in part; (b) the Company and any other
party liable for payment under the Indenture or under the Note may be granted
indulgences generally; (c) any of the provisions of this Note or the Indenture
may be modified, amended or waived; and (d) any party (including any Subsidiary
Guarantor) liable for the payment under this Note or under the Indenture may be granted indulgences or be released;
all without notice to or further assent by such Subsidiary Guarantor, which
shall remain bound thereon, notwithstanding any such exchange, compromise,
surrender, extension, renewal, acceleration, modification, indulgence or
release. 

                    Waiver of Rights. Each of the Subsidiary
Guarantors hereby waives to the fullest extent permitted by law: (a) notice of acceptance of this Guarantee
by the Holder of this Note; (b) presentment and demand for payment or
performance of any of the Guarantor Obligations; (c) protest and notice of
dishonor or default with respect to the Guarantor Obligations; (d) all other
notices to which such Subsidiary Guarantor might otherwise be entitled.  

                    Reinstatement. The obligations of the Subsidiary Guarantors
under this Note and under Article Sixteen shall be automatically reinstated if
and to the extent that for any reason any payment by or on behalf of any Person
in respect of the Guarantor Obligations is rescinded or must otherwise be
restored by any Holder of the Notes of this series, whether as a result of any
proceedings in bankruptcy or reorganization or otherwise. 

                    Remedies. Each of the Subsidiary Guarantors further
agrees, to the fullest extent that it may lawfully do so, that as between each
such Subsidiary Guarantor, on the one hand, and the Holder and the Trustee, on
the other hand, the maturity of the obligations guaranteed hereby may be
accelerated as provided in Article Five of the Indenture for the purposes of
this guarantee, notwithstanding any stay, injunction or other prohibition
extant under any applicable bankruptcy law preventing such acceleration in
respect of the obligations guaranteed hereby. 

                    Rights
of Contribution. The Subsidiary
Guarantors, in connection with payments made hereunder, shall have contribution
rights against the other Subsidiary Guarantors as permitted under applicable
law. Such contribution rights shall be
subordinate and subject in right of payment to the obligations of the
Subsidiary Guarantors under this Note and no Subsidiary Guarantor shall
exercise such rights of contribution until all Guarantor Obligations have been
paid in full.

                    Limitation
of Guaranty. Notwithstanding any
provision to the contrary contained herein or in the Indenture, to the extent the
obligations of any Subsidiary Guarantor shall be adjudicated to be invalid or
unenforceable for any reason (including, without limitation, because of any
applicable state or federal law relating to fraudulent conveyances or
transfers) then the obligations of the Subsidiary Guarantors hereunder shall be
limited to the maximum amount that is permissible under applicable law (whether federal or state or otherwise and
including, without limitation, the Bankruptcy Code).

B-10

                    Release
of Guarantors. Each of the
Subsidiary Guarantors hereby covenants that its Subsidiary Guarantee will not
be discharged except by complete performance of its obligations contained in
the Note, this Subsidiary Guarantee and pursuant to the Indenture; provided, however, that if (a) an Subsidiary Guarantor does not
guarantee any Indebtedness of the Company the amount of which, when added
together with any other outstanding Indebtedness of the Company guaranteed by
its Subsidiaries that are not Subsidiary Guarantors, would exceed $50 million
in the aggregate, excluding the Notes of this series, and all outstanding
Indebtedness of such Subsidiary Guarantor would have been permitted to be
incurred pursuant to Section 1011 of the Indenture measured at the time of
the release and discharge as described in this paragraph, (b) the Notes of this
series are defeased and discharged pursuant to Article Fourteen of the
Indenture, or (c) all or substantially all of the assets of such Subsidiary
Guarantor or all of the capital stock of such Subsidiary Guarantor is sold
(including by issuance, merger, consolidation or otherwise) by the Company or
any of its Subsidiaries, then in each case of (a), (b) or (c) above, such
Subsidiary Guarantor or the corporation acquiring such assets (in the event of
a sale or other disposition of all or substantially all of the assets or
capital stock of such Subsidiary Guarantor) shall be automatically and without
any further action on the part of any party to the Indenture, and upon notice
to the Trustee, be fully released and discharged from all its liabilities and
obligations under or in respect of the Indenture and this Subsidiary Guarantee
of the Note, and promptly upon the request of the Company and at the expense of
the Company, the Trustee shall execute such documents and take such other
action as is reasonably requested by the Company to evidence the release and
discharge of such Guarantor from all such liabilities and obligations and
shall, if applicable, certify to the Company that such Subsidiary Guarantor has
no liabilities or obligations resulting from a demand on such Subsidiary
Guarantor’s Guarantee. 

                    Defined
Terms. All terms used in this Note,
which are defined in the Indenture and are not otherwise defined herein, shall
have the meanings assigned to them in the Indenture. 

                    Governing
Law. This Subsidiary Guarantee
shall be governed by and construed in accordance with the law of the State of
New York.

                    Subject
to the next following paragraph, each Subsidiary Guarantor hereby certifies and
warrants that all acts, conditions and things required to be done and performed
and to have happened precedent to the creation and issuance of this Subsidiary
Guarantee and to constitute the same valid obligation of each Subsidiary
Guarantor have been done and performed and have happened in due compliance with
all applicable laws.

(Remainder of page intentionally left blank.)

B-11

This
Subsidiary Guarantee shall not be valid or become obligatory for any purpose
until the certificate of authentication on the Note upon which this Subsidiary
Guarantee is endorsed has been signed by the Trustee under the Indenture
referred to in this Note.

Dated: March 24, 2011

	
  

 	
  

 
	
  

 	
 AMERICAN MEDICAL LABORATORIES, INCORPORATED
AMERIPATH,
 INC.

 AMERIPATH CONSOLIDATED LABS, INC.

 AMERIPATH FLORIDA, LLC 

 
	
  

 	
 AMERIPATH
 GROUP HOLDINGS, INC.

 
	
  

 	
 AMERIPATH
 HOLDINGS, INC.

 
	
  

 	
 AMERIPATH
 HOSPITAL SERVICES FLORIDA, LLC

 AMERIPATH INDIANA, LLC 

 
	
  

 	
 AMERIPATH
 INTERMEDIATE HOLDINGS, INC.

 
	
  

 	
 AMERIPATH
 KENTUCKY, INC.

 AMERIPATH MARKETING USA, INC. AMERIPATH MICHIGAN, INC.

 AMERIPATH MISSISSIPPI, INC.

 AMERIPATH NEW YORK, LLC

 AMERIPATH NORTH CAROLINA, INC.

 AMERIPATH OHIO, INC.

 AMERIPATH PENNSYLVANIA, LLC

 AMERIPATH PHILADELPHIA, INC.

 AMERIPATH SC, INC.

 AMERIPATH TEXAS, L.P.

 AMERIPATH YOUNGSTOWN LABS, INC.

 AMERIPATH WISCONSIN, LLC

 AMERIPATH, LLC API NO. 2, LLC

 
	
  

 	
 ANATOMIC
 PATHOLOGY SERVICES, INC. 

 
	
  

 	
 ARIZONA
 PATHOLOGY GROUP, INC. 

 
	
  

 	
 APL
 PROPERTIES LIMITED LIABILITY COMPANY

 
	
  

 	
 CENTRAL
 PLAINS HOLDINGS, INC.

 
	
  

 	
 DERMATOPATHOLOGY
 SERVICES, INC.

 DIAGNOSTIC PATHOLOGY MANAGEMENT SERVICES, LLC

 
	
  

 	
 DIAGNOSTIC
 REFERENCE SERVICES, INC.

 
	
  

 	
 DPD
 HOLDINGS, INC.

 
	
  

 	
 ENTERIX INC.
 EXAMONE WORLD WIDE, INC.

 
	
  

 	
 EXAMONE
 WORLD WIDE OF NJ, INC.

 
	
  

 	
 FOCUS
 TECHNOLOGIES HOLDING COMPANY FOCUS DIAGNOSTICS, INC.

 
	
  

 	
 HEMOCUE,
 INC.

 

B-12

	
  

 	
  

 
	
  

 	
 KAILASH B.
 SHARMA, M.D., INC.

 
	
  

 	
 LABONE, INC.

 
	
  

 	
 LABONE OF
 OHIO, INC.

 
	
  

 	
 MEDPLUS,
 INC.

 
	
  

 	
 METWEST INC.

 
	
  

 	
 NICHOLS
 INSTITUTE DIAGNOSTICS

 
	
  

 	
 OSBORN GROUP
 INC.

 
	
  

 	
 OCMULGEE
 MEDICAL PATHOLOGY ASSOCIATION, INC.

 
	
  

 	
 O’QUINN MEDICAL
 PATHOLOGY ASSOCIATION, LLC

 
	
  

 	
 PATHOLOGY
 BUILDING PARTNERSHIP

 
	
  

 	
 PCA OF
 DENVER, INC. 

 
	
  

 	
 PCA OF
 NASHVILLE, INC. 

 
	
  

 	
 PETER G.
 KLACSMANN M.D., INC. 

 
	
  

 	
 QUEST
 DIAGNOSTICS HOLDINGS INCORPORATED

 
	
  

 	
 QUEST
 DIAGNOSTICS CLINICAL LABORATORIES, INC.

 
	
  

 	
 QUEST
 DIAGNOSTICS NICHOLS INSTITUTE

 
	
  

 	
 QUEST
 DIAGNOSTICS FINANCE INCORPORATED

 
	
  

 	
 QUEST
 DIAGNOSTICS INVESTMENTS INCORPORATED

 
	
  

 	
 QUEST
 DIAGNOSTICS INCORPORATED (NV)

 
	
  

 	
 QUEST DIAGNOSTICS INCORPORATED (MD)

 
	
  

 	
 QUEST DIAGNOSTICS LLC (IL)

 
	
  

 	
 QUEST DIAGNOSTICS LLC (CT)

 
	
  

 	
 QUEST DIAGNOSTICS LLC (MA)

 
	
  

 	
 QUEST
 DIAGNOSTICS INCORPORATED (MI)

 
	
  

 	
 QUEST
 DIAGNOSTICS OF PENNSYLVANIA INC.

 
	
  

 	
 QUEST
 DIAGNOSTICS NICHOLS INSTITUTE, INC.

 
	
  

 	
 REGIONAL
 PATHOLOGY CONSULTANTS, LLC 

 
	
  

 	
 ROCKY
 MOUNTAIN PATHOLOGY, LLC

 
	
  

 	
 SHARON G.
 DASPIT, M.D., INC. SHOALS PATHOLOGY ASSOCIATES, INC.

 
	
  

 	
 SPECIALTY
 LABORATORIES, INC.

 
	
  

 	
 STRIGEN,
 INC. 

 
	
  

 	
 TID
 ACQUISITION CORP. 

 
	
  

 	
 UNILAB
 CORPORATION

 

B-13

	
  

 	
  

 
	
  

 	
 QUEST
 DIAGNOSTICS INVESTMENTS INCORPORATED
QUEST DIAGNOSTICS FINANCE INCORPORATED

 

	
  

 	
  

 	
  

 	
  

 
	
  

 	
 By:

 	

  

 	
  

 
	
  

 	
  

 	

 

 	
  

 
	
  

 	
  

 	
 Name:

 	
  

 
	
  

 	
  

 	
 Title:

 	
  

 

	
  

 	
  

 	
  

 	
  

 
	
 Attest:

 	
  

 
	
  

 	
  

 
	
 By:

 	
 

 	
  

 
	
  

 	

 

 	
  

 
	
 Name: 

 	
 William J.
 O’Shaughnessy, Jr. 

 	
  

 
	
 Title:

 	
 Assistant
 General Counsel

 	
  

 
	
  

 	
  

 	
 and
 Corporate Secretary

 	
  

 

B-14

EXHIBIT C

Form of Floating Rate Senior Notes due 2014

                    [The following legends apply only if the Note is a
Global Note:

                    THIS
NOTE IS A GLOBAL NOTE WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED
TO AND IS REGISTERED IN THE NAME OF A DEPOSITORY OR A NOMINEE THEREOF. THIS NOTE MAY NOT BE EXCHANGED IN WHOLE OR
IN PART FOR A NOTE REGISTERED, AND NO TRANSFER OF THIS NOTE IN WHOLE OR IN PART
MAY BE REGISTERED, IN THE NAME OF ANY PERSON OTHER THAN SUCH DEPOSITORY OR ITS
NOMINEE EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE.

                    UNLESS
THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY
TRUST COMPANY TO THE ISSUER OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE
OR PAYMENT AND SUCH CERTIFICATE ISSUED IN EXCHANGE FOR THIS CERTIFICATE IS
REGISTERED IN THE NAME OF CEDE & CO., OR SUCH OTHER NAME AS REQUESTED BY AN
AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY, ANY TRANSFER, PLEDGE OR OTHER USE
HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL, SINCE THE
REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN.]

C-1

QUEST DIAGNOSTICS INCORPORATED

Floating Rate Senior Notes due 2014

Unconditionally guaranteed as to payment of

principal of and interest by

the Subsidiary Guarantors

	
  

 	
  

 
	
 No.
 0 (Specimen)

 	
 $200,000,000

 

CUSIP:
74834L
AT7

                    Quest
Diagnostics Incorporated, a Delaware corporation (herein called the “Company,”
which term includes any successor Person under the Indenture hereinafter
referred to), for value received, hereby promises to pay to Cede & Co., or
registered assigns, the principal sum of $200,000,000 on March 24, 2014 (the “Stated Maturity”) (except to the
extent redeemed or repaid prior to the Stated Maturity) and to pay interest
thereon from March 24, 2011 or
from the most recent Interest Payment Date to which interest has been paid or
duly provided for quarterly at a per annum rate equal to three-month LIBOR
(calculated as described in the Indenture) for the applicable Interest Reset
Period or Initial Interest Period (each as defined in the Indenture) plus 0.85%
(85 basis points), reset quarterly, on March 24, June 24, September 24 and
December 24, commencing with June 24, 2011, on the Stated Maturity and on any
Redemption Date (each such date, an “Interest Payment Date”) until the
principal hereof is paid or made available for payment. 

                    Payment
of Interest. The interest so
payable, and punctually paid or made available for payment, on any Interest
Payment Date, will, as provided in the Indenture, be paid, in immediately
available funds, to the Person in whose name this Note (or one or more
Predecessor Securities) is registered at the close of business on March 9, June
9, September 9 or December 9, as the case may be (whether or not a Business
Day, as defined in the Indenture), as the case may be, next preceding such
Interest Payment Date (the “Regular Record Date”). Any such interest not punctually paid or duly provided for
(“Defaulted Interest”) will forthwith cease to be payable to the Holder on such
Regular Record Date, and such Defaulted Interest, may be paid to the Person in
whose name this Note (or one or more Predecessor Securities) is registered at
the close of business on a special record date (the “Special Record Date”) for
the payment of such Defaulted Interest to be fixed by the Trustee, notice
whereof shall be given to Holders of Notes not less than ten days prior to such
Special Record Date, or may be paid at any time in any other lawful manner not
inconsistent with requirements of any securities exchange on which the Notes
may be listed, and upon such notice as may be required by such exchange, all as
more fully provided in said Indenture. 

                    Place
of Payment. Payment of interest on this
Note will be made at the Corporate Trust Office of the Trustee or such other
office or agency of the Company as may be designated for such purpose, in such
coin or currency of the United States of America as at the time of payment is
legal tender for payment of public and private debts; provided, however, that
each installment of interest and payment of principal on this Notes may at the
Company’s option be paid in immediately available funds by transfer to an
account maintained by the payee located in the United States. Payment of the principal of this Note on the
Stated Maturity will be made against presentation of this Note at the office or
agency of the Company maintained for that 

C-2

purpose in the
Borough of Manhattan, The City of New York, in such coin or currency of the
United States of America as at the time of payment is legal tender for the
payment of public and private debts.

                    Time
of Payment. In any case where any
Interest Payment Date(other than the Maturity date) is not a Business Day at
the relevant place of payment, the Company will pay interest on the next day
that is a Business Day at such place of payment as if payment were made on the
date such payment was due, and no interest will accrue on the amounts so
payable for the period from and after such date to the immediately succeeding
Business Day, except that if such Business Day is in the immediately succeeding
calendar month, such interest payment date (other than the Maturity date) shall
be the immediately preceding Business Day. If the Maturity date of the Floating
Rate Notes is not a Business Day at the relevant place of payment, the Company
will pay interest, if any, and principal and premium, if any, on the next day
that is a Business Day at such place of payment as if payment were made on the
date such payment was due, and no interest will accrue on the amounts so
payable for the period from and after such date to the immediately succeeding
Business Day.

                    Legends. The statements set forth in the restrictive
legends above are an integral part of the terms of this Note and by acceptance
hereof each Holder of this Note agrees to be subject to and bound by the terms
and provisions set forth in such legend.

                    General. This Note is one of a duly authorized issue
of securities (herein called the “Securities”) of the Company, issued and to be
issued in one or more series under an indenture, dated as of June 27, 2001
(the “Base Indenture”), between the Company and The Bank of New York, Trustee
(herein called the “Trustee”, which term includes any successor trustee under
the Indenture with respect to a series of which this Note is a part), to which
Base Indenture and all indentures supplemental thereto, including the
supplemental indenture dated March 24, 2011 (the “Supplemental Indenture”), reference is
hereby made for a statement of the respective rights, limitations of rights,
duties and immunities thereunder of the Company, the Trustee and the Holders of
the Securities, and of the terms upon which the Securities are, and are to be,
authenticated and delivered. This Note
is one of a duly authorized series of Securities designated as “Floating Rate
Senior Notes due 2014”
(collectively, the “Notes”), initially limited in aggregate principal amount to
$200,000,000.

                    Further
Issuance. The Company may from time
to time, without the consent of the Holders of Notes of this series, issue
additional Notes (the “Additional Notes”) of this series having the same
ranking and the same interest rate, maturity and other terms as the Notes of
this series. Any Additional Notes of
this series and the Notes of this series will constitute a single series under
the Indenture and all references to the Notes of this series shall include the
Additional Notes unless the context otherwise requires. 

                    [The following paragraph applies only if the Note is a
Global Note:

                    Book-Entry. This Note is a Global Note representing $200,000,000 of the Notes. This Note is a “book entry” Note and is
being registered in the name of Cede & Co. as nominee of The Depository
Trust Company (the “Depository “), a clearing agency. Subject to the terms of the Indenture, this Note will be held by
a clearing agency or its nominee, and beneficial interest will be held by
beneficial owners through the book-entry facilities of such clearing agency or
its nominee in minimum denominations of $2,000 and integral multiples of $1,000
in 

C-3

excess
thereof. As long as this Note is
registered in the name of the Depository or its nominee, the Trustee will make
payments of principal and interest on this Note by wire transfer of immediately
available funds to the Depository or its nominee. Notwithstanding the above, the final payment on this Note will be
made after due notice by the Trustee of the pendency of such payment and only
upon presentation and surrender of this Note at its Corporate Trust Office or
such other offices or agencies appointed by the Trustee for that purpose and
such other locations provided in the Indenture.]

                    Guarantees. This Note is entitled to the benefits of the
Subsidiary Guarantees by each of the Subsidiary Guarantors of the due and
punctual payment and performance of the Guarantor Obligations made in favor of
the Trustee for the benefit of the Holder of this Note. Reference is hereby made to Article Sixteen
of the Indenture for a statement of the respective rights, limitations of
rights, duties and obligations under the Guarantees of each of the
Guarantors.  

                    Events
of Default. If an Event of Default
with respect to the Notes shall have occurred and be continuing, the principal
of the Notes of this series may be declared due and payable in the manner and
with the effect provided in the Indenture.

                    Optional
Redemption. The Notes of this series are not subject to any sinking
fund. The notes of this series may not
be redeemed prior to maturity, other than as described under “Special Mandatory
Redemption.”

                    Special
Mandatory Redemption. If the
Company has failed to consummate the acquisition of Athena Diagnostics, Inc. on
or prior to October 31, 2011, or the related Stock Purchase and Sale Agreement,
dated as of February 23, 2011, between Thermo Fisher Scientific Inc., a
Delaware corporation and the Company (“the Stock Purchase and Sale Agreement”)
is terminated at any time prior thereto, then the Company must redeem all of
the Notes of this series on the Special Mandatory Redemption Date (as defined
below) at a redemption price equal to 101% of the aggregate principal amount of
the Notes, plus accrued and unpaid interest from the date of initial issuance
to, but excluding, the Special Mandatory Redemption Date (subject to the right
of holders of record on the relevant record date to receive interest due on the
relevant Interest Payment Date). The “Special Mandatory Redemption Date” means
the earlier to occur of (1) November 15, 2011, if the acquisition of Athena
Diagnostics, Inc. has not been completed on or prior to October 31, 2011, or
(2) the 30th day (or if such day is not a Business Day, the first Business Day
thereafter) following the termination of the Stock Purchase and Sale Agreement
for any reason. 

                    Redemption
upon a Change of Control Triggering Event.
Upon the occurrence of a Change of Control Triggering Event, the Company
shall be required to make an offer to repurchase the Notes on the terms set
forth in the Indenture.

                    Defeasance
and Covenant Defeasance. The Indenture
contains provisions for defeasance at any time of (a) the entire indebtedness
of the Company on this Note and (b) certain restrictive covenants and the
related Defaults and Events of Default, upon compliance by the Company with
certain conditions set forth therein, which provisions apply to this Note. 

                    Modification
and Waivers; Obligations of the Company Absolute. The Indenture permits, with certain exceptions as therein
provided, the amendment thereof and the modification 

C-4

of the rights
and obligations of the Company and the rights of the Holders of the Securities
of each series. Such amendment may be
effected under the Indenture at any time by the Company, the Subsidiary
Guarantors and the Trustee with the consent of the Holders of not less than a
majority in aggregate principal amount of the Outstanding Notes of each series
affected thereby. The Indenture also
contains provisions permitting the Holders of not less than a majority in
aggregate principal amount of the Securities at the time Outstanding, on behalf
of the Holders of all Outstanding Securities, to waive compliance by the
Company with certain provisions of the Indenture. Furthermore, provisions in the Indenture permit the Holders of
not less than a majority in aggregate principal amount of the Outstanding
Securities of individual series to waive on behalf of all of the Holders of
Securities of such individual series certain past defaults under the Indenture
and their consequences. Any such
consent or waiver shall be conclusive and binding upon the Holder of this Note
and upon all future Holders of this Note and of any Note issued upon the
registration of transfer hereof or in exchange hereof or in lieu hereof,
whether or not notation of such consent or waiver is made upon this Note. 

                    No
reference herein to the Indenture and no provision of this Note or of the
Indenture shall alter or impair the obligation of the Company, which is
absolute and unconditional, to pay the principal of and interest on this Note
at the time, place, and rate, and in the coin or currency, herein prescribed.

                    Limitation
on Suits. As set forth in, and
subject to, the provisions of the Indenture, no Holder of any Note of this
series will have any right to institute any proceeding with respect to the
Indenture or for any remedy thereunder, unless such Holder shall have
previously given to the Trustee written notice of a continuing Event of Default
with respect to this series, the Holders of not less than 25% in principal
amount of the Outstanding Notes of this series shall have made written request,
and offered reasonable indemnity, to the Trustee to institute such proceedings
as trustee, and the Trustee shall not have received from the Holders of a
majority in principal amount of the Outstanding Notes of this series a direction
inconsistent with such request and shall have failed to institute such
proceeding within 60 days; provided,
however, that such limitations do
not apply to a suit instituted by the Holder hereof for the enforcement of
payment of the principal of or interest on this Note on or after the respective
due dates expressed herein. 

                    Authorized
Denominations. The Notes of this
series are issuable only in registered form without coupons in denominations of
$2,000 or any integral multiple of $1,000 in excess thereof.

                    Registration
of Transfer or Exchange. As
provided in the Indenture and subject to certain limitations herein and therein
set forth, the transfer of this Note is registrable in the Security Register
upon surrender of this Note for registration of transfer at the office or
agency of the Company in any place where the principal of and interest on this
Note are payable, duly endorsed by, or accompanied by a written instrument of
transfer in form satisfactory to the Company and the Security Registrar duly
executed by, the Holder hereof or his attorney duly authorized in writing, and
thereupon one or more new Notes, of authorized denominations and for the same
aggregate principal amount, will be issued to the designated transferee or
transferees.

C-5

                    As
provided in the Indenture and subject to certain limitations herein and therein
set forth, the Notes are exchangeable for a like aggregate principal amount of
Notes of different authorized denominations, as requested by the Holders
surrendering the same.

                    [The following paragraph applies only if the Note is a
Global Note:

                    This
      Note is a Global Security. If the
      Depository is at any time unwilling, unable or ineligible to continue as depository
      and a successor depository is not appointed by the Company within 90 days or an
      Event of Default under the Indenture has occurred and is continuing, the
      Company will issue Securities in certificated form in exchange for each Global
      Security. In addition, the Company may
      at any time determine not to have Securities represented by a Global Security
      and, in such event, will issue Securities in certificated form in exchange in
      whole for the Global Security representing such Security. In any such instance, an owner of a
      beneficial interest in a Global Security will be entitled to physical delivery
      in certificated form of Securities equal in principal amount to such beneficial
      interest and to have such Securities registered in its name. Securities so issued in certificated form
      will be issued in denominations of $2,000 or any amount in excess thereof which
      is an integral multiple of $1,000 and will be issued in registered form only,
  without coupons.

                    No
service charge shall be made for any such registration of transfer or exchange,
but the Company may require payment of a sum sufficient to cover any tax or
other governmental charge payable in connection therewith.

                    Prior
to due presentment of this Note for registration of transfer, the Company, the
Trustee and any agent of the Company or the Trustee may treat the Holder as the
owner hereof for all purposes, whether or not this Note be overdue, and neither
the Company, the Trustee nor any such agent shall be affected by notice to the
contrary.]

                    Defined
Terms. All terms used in this Note,
which are defined in the Indenture and are not otherwise defined herein, shall
have the meanings assigned to them in the Indenture. 

                    Governing
Law. This Note shall be governed by
and construed in accordance with the law of the State of New York.

                    Unless
the certificate of authentication hereon has been executed by the Trustee by
manual signature, this Note shall not be entitled to any benefit under the
Indenture or be valid or obligatory for any purpose.

C-6

                    IN
WITNESS WHEREOF, the Company has caused this instrument to be duly executed.

Dated: March 24, 2011

	
  

 	
  

 	
  

 	
  

 
	
  

 	
 QUEST
 DIAGNOSTICS INCORPORATED

 
	
  

 	
  

 
	
  

 	
 By:

 	
  

 
	
  

 	
  

 	

 

 
	
  

 	
 Name:

 	
 Robert
 O’Keef

 
	
 Attest:

 	
 Title:

 	
 Vice
 President and Treasurer

 

	
  

 	
  

 	
  

 	
  

 
	
 By:

 	
  

 	
  

 
	
  

 	

 

 	
  

 
	
 Name:

 	
  William J. O’Shaughnessy, Jr.

 	
  

 
	
 Title:

 	
 Assistant
 General Counsel and Corporate Secretary

 
	
  

 	
  

 	
  

 

C-7

TRUSTEE’S CERTIFICATE OF AUTHENTICATION

                    This
is one of the Notes of the series designated and referred to in the
within-mentioned Indenture, as such is supplemented by the within-mentioned
Fourteenth Supplemental Indenture.

	
  

 	
  

 	
  

 	
  

 
	
  

 	
 THE BANK OF
 NEW YORK MELLON

 
	
  

 	
 as Trustee

 
	
  

 	
  

 
	
  

 	
 By:

 	
  

 	
  

 
	
  

 	
  

 	

 

 	
  

 
	
  

 	
  

 	
 Name:

 	
  

 
	
  

 	
  

 	
 Title:

 	
  

 

Dated: March 24, 2011

C-8

GUARANTEE OF THE SUBSIDIARY GUARANTORS

                    FOR
VALUE RECEIVED, each of the Subsidiary Guarantors (as such term is defined in
the Indenture, as amended by the First Supplemental Indenture, the Second
Supplemental Indenture, the Third Supplemental Indenture, the Fourth
Supplemental Indenture, the Fifth Supplemental Indenture, the Sixth
Supplemental Indenture, the Seventh Supplemental Indenture, the Eighth
Supplemental Indenture, the Ninth Supplemental Indenture, the Tenth
Supplemental Indenture, the Eleventh Supplemental Indenture, the Twelfth
Supplemental Indenture, the Thirteenth Supplemental Indenture and the
Fourteenth Supplemental Indenture), hereby, jointly and severally,
unconditionally guarantees to the Holder of the Note upon which this Subsidiary
Guarantee is endorsed (the “Note”) and to the Trustee on behalf of the Holder,
the prompt payment of the principal of (and premium, if any, on) and interest
(including, in case of default, interest on principal and, to the extent
permitted by applicable law, on overdue interest and including any additional
interest required to be paid according to the terms of the Notes) on the Note,
when due (whether at Stated Maturity, upon Redemption, upon acceleration, upon
tender for repayment at the option of the Company), according to the terms
hereof and the terms of the Indenture (the “Guarantor Obligations”). This
Guarantee is a guarantee of payment and not of collection and is a continuing
guarantee and shall apply to all Guarantor Obligations whenever arising. 

                    Obligations
Unconditional and Absolute. The obligations of the Subsidiary Guarantors
hereunder are absolute and unconditional irrespective of the value,
genuineness, validity, regularity or enforceability of the Indenture or this
Note, to the fullest extent permitted by applicable law, irrespective of any
circumstance whatsoever which might otherwise constitute a legal or equitable
discharge or defense of a surety or guarantor. Each of the Subsidiary
Guarantors agrees that this Guarantee may be enforced by the Holder of this
Note without the necessity at any time of proceeding against the Company or any
other Person (including a co-guarantor) or to pursue any other remedy or
enforce any other right. Each of the Subsidiary Guarantors further agrees that
nothing contained herein shall prevent the Holder of this Note from suing on
this Note or the Indenture or from exercising any other rights available under
this Note and the Indenture, and the exercise of any of the aforesaid rights
and shall not constitute a discharge of any Subsidiary Guarantor’s obligations
hereunder and under the Indenture; it being the purpose and the intent of each
Subsidiary Guarantor that its obligations under this Note and under the
Indenture shall be absolute, independent and unconditional under any and all
circumstances. Neither any Subsidiary Guarantor’s obligations under this
Guarantee nor any remedy for the enforcement thereof shall be impaired,
modified, changed or released in any manner whatsoever by an impairment,
modification, change, release or limitation of the liability of the Company or
by reason of the bankruptcy or insolvency of the Company. Each Subsidiary
Guarantor waives any and all notice of the creation, renewal, extension or
accrual of any of the Guarantor Obligations or acceptance of this Guarantee.
The Guarantor Obligations, and any of them, shall conclusively be deemed to
have been created, contracted or incurred, or renewed, extended, amended or
waived, in reliance upon this Guarantee. 

                    Subrogation.
Each of the Subsidiary Guarantors shall be subrogated to all rights of the
Holder of the Note against the Company in respect of any amounts paid by such
Subsidiary Guarantor on account of the Note or the Indenture; provided, however,
that such Subsidiary Guarantor shall not be entitled to enforce or to receive
any payments arising out of, or 

C-9

based upon,
such right of subrogation until the principal of (or premium, if any, on) and
interest on all Notes of this series shall have been indefeasibly paid in full.

                    Modifications.
Each Subsidiary Guarantor agrees that (a) the time or place of payment of the
Guarantor Obligations may be changed or extended, in whole or in part, to a
time certain or otherwise, and may be renewed or accelerated, in whole or in
part; (b) the Company and any other party liable for payment under the
Indenture or under the Note may be granted indulgences generally; (c) any of
the provisions of this Note or the Indenture may be modified, amended or
waived; and (d) any party (including any Subsidiary Guarantor) liable for the
payment under this Note or under the Indenture may be granted indulgences or be
released; all without notice to or further assent by such Subsidiary Guarantor,
which shall remain bound thereon, notwithstanding any such exchange,
compromise, surrender, extension, renewal, acceleration, modification,
indulgence or release. 

                    Waiver
of Rights. Each of the Subsidiary Guarantors hereby waives to the fullest
extent permitted by law: (a) notice of acceptance of this Guarantee by the
Holder of this Note; (b) presentment and demand for payment or performance of
any of the Guarantor Obligations; (c) protest and notice of dishonor or default
with respect to the Guarantor Obligations; (d) all other notices to which such
Subsidiary Guarantor might otherwise be entitled. 

                    Reinstatement.
The obligations of the Subsidiary Guarantors under this Note and under Article
Sixteen shall be automatically reinstated if and to the extent that for any
reason any payment by or on behalf of any Person in respect of the Guarantor
Obligations is rescinded or must otherwise be restored by any Holder of the
Notes of this series, whether as a result of any proceedings in bankruptcy or
reorganization or otherwise. 

                    Remedies.
Each of the Subsidiary Guarantors further agrees, to the fullest extent that it
may lawfully do so, that as between each such Subsidiary Guarantor, on the one
hand, and the Holder and the Trustee, on the other hand, the maturity of the
obligations guaranteed hereby may be accelerated as provided in Article Five of
the Indenture for the purposes of this guarantee, notwithstanding any stay,
injunction or other prohibition extant under any applicable bankruptcy law
preventing such acceleration in respect of the obligations guaranteed hereby. 

                    Rights
of Contribution. The Subsidiary Guarantors, in connection with payments
made hereunder, shall have contribution rights against the other Subsidiary
Guarantors as permitted under applicable law. Such contribution rights shall be
subordinate and subject in right of payment to the obligations of the
Subsidiary Guarantors under this Note and no Subsidiary Guarantor shall
exercise such rights of contribution until all Guarantor Obligations have been
paid in full. 

                    Limitation
of Guaranty. Notwithstanding any provision to the contrary contained herein
or in the Indenture, to the extent the obligations of any Subsidiary Guarantor
shall be adjudicated to be invalid or unenforceable for any reason (including,
without limitation, because of any applicable state or federal law relating to
fraudulent conveyances or transfers) then the obligations of the Subsidiary
Guarantors hereunder shall be limited to the maximum amount that is permissible
under applicable law (whether federal or state or otherwise and including,
without limitation, the Bankruptcy Code). 

C-10

                    Release
of Guarantors. Each of the Subsidiary Guarantors hereby covenants that its
Subsidiary Guarantee will not be discharged except by complete performance of
its obligations contained in the Note, this Subsidiary Guarantee and pursuant
to the Indenture; provided, however, that if (a) an Subsidiary
Guarantor does not guarantee any Indebtedness of the Company the amount of
which, when added together with any other outstanding Indebtedness of the
Company guaranteed by its Subsidiaries that are not Subsidiary Guarantors,
would exceed $50 million in the aggregate, excluding the Notes of this series,
and all outstanding Indebtedness of such Subsidiary Guarantor would have been
permitted to be incurred pursuant to Section 1011 of the Indenture measured at
the time of the release and discharge as described in this paragraph, (b) the
Notes of this series are defeased and discharged pursuant to Article Fourteen
of the Indenture, or (c) all or substantially all of the assets of such
Subsidiary Guarantor or all of the capital stock of such Subsidiary Guarantor
is sold (including by issuance, merger, consolidation or otherwise) by the
Company or any of its Subsidiaries, then in each case of (a), (b) or (c) above,
such Subsidiary Guarantor or the corporation acquiring such assets (in the event
of a sale or other disposition of all or substantially all of the assets or
capital stock of such Subsidiary Guarantor) shall be automatically and without
any further action on the part of any party to the Indenture, and upon notice
to the Trustee, be fully released and discharged from all its liabilities and
obligations under or in respect of the Indenture and this Subsidiary Guarantee
of the Note, and promptly upon the request of the Company and at the expense of
the Company, the Trustee shall execute such documents and take such other
action as is reasonably requested by the Company to evidence the release and
discharge of such Guarantor from all such liabilities and obligations and
shall, if applicable, certify to the Company that such Subsidiary Guarantor has
no liabilities or obligations resulting from a demand on such Subsidiary
Guarantor’s Guarantee. 

                    Defined
Terms. All terms used in this Note, which are defined in the Indenture and
are not otherwise defined herein, shall have the meanings assigned to them in
the Indenture.

                    Governing Law. This Subsidiary Guarantee
shall be governed by and construed in accordance with the law of the State of
New York. 

                    Subject
to the next following paragraph, each Subsidiary Guarantor hereby certifies and
warrants that all acts, conditions and things required to be done and performed
and to have happened precedent to the creation and issuance of this Subsidiary
Guarantee and to constitute the same valid obligation of each Subsidiary
Guarantor have been done and performed and have happened in due compliance with
all applicable laws. 

(Remainder of page intentionally left blank.)

C-11

This Subsidiary Guarantee shall not be valid
or become obligatory for any purpose until the certificate of authentication on
the Note upon which this Subsidiary Guarantee is endorsed has been signed by
the Trustee under the Indenture referred to in this Note.

Dated: March
24, 2011 

	
  

 	
  

 
	
  

 	
 AMERICAN
 MEDICAL LABORATORIES, INCORPORATED

 
	
  

 	
 AMERIPATH,
 INC.

 
	
  

 	
 AMERIPATH
 CONSOLIDATED LABS, INC.

 
	
  

 	
 AMERIPATH
 FLORIDA, LLC

 
	
  

 	
 AMERIPATH
 GROUP HOLDINGS, INC.

 
	
  

 	
 AMERIPATH
 HOLDINGS, INC.

 
	
  

 	
 AMERIPATH
 HOSPITAL SERVICES FLORIDA, LLC

 
	
  

 	
 AMERIPATH
 INDIANA, LLC

 
	
  

 	
 AMERIPATH
 INTERMEDIATE HOLDINGS, INC.

 
	
  

 	
 AMERIPATH
 KENTUCKY, INC.

 
	
  

 	
 AMERIPATH
 MARKETING USA, INC.

 
	
  

 	
 AMERIPATH
 MICHIGAN, INC.

 
	
  

 	
 AMERIPATH
 MISSISSIPPI, INC.

 
	
  

 	
 AMERIPATH
 NEW YORK, LLC

 
	
  

 	
 AMERIPATH
 NORTH CAROLINA, INC.

 
	
  

 	
 AMERIPATH
 OHIO, INC.

 
	
  

 	
 AMERIPATH
 PENNSYLVANIA, LLC

 
	
  

 	
 AMERIPATH
 PHILADELPHIA, INC.

 
	
  

 	
 AMERIPATH
 SC, INC.

 
	
  

 	
 AMERIPATH
 TEXAS, L.P.

 
	
  

 	
 AMERIPATH
 YOUNGSTOWN LABS, INC.

 
	
  

 	
 AMERIPATH
 WISCONSIN, LLC

 
	
  

 	
 AMERIPATH,
 LLC

 
	
  

 	
 API NO. 2,
 LLC

 
	
  

 	
 ANATOMIC
 PATHOLOGY SERVICES, INC.

 
	
  

 	
 ARIZONA
 PATHOLOGY GROUP, INC.

 
	
  

 	
 APL
 PROPERTIES LIMITED LIABILITY COMPANY

 
	
  

 	
 CENTRAL PLAINS
 HOLDINGS, INC.

 
	
  

 	
 DERMATOPATHOLOGY
 SERVICES, INC.

 
	
  

 	
 DIAGNOSTIC
 PATHOLOGY MANAGEMENT SERVICES, LLC

 
	
  

 	
 DIAGNOSTIC
 REFERENCE SERVICES, INC.

 
	
  

 	
 DPD
 HOLDINGS, INC.

 
	
  

 	
 ENTERIX INC.

 
	
  

 	
 EXAMONE
 WORLD WIDE, INC.

 
	
  

 	
 EXAMONE
 WORLD WIDE OF NJ, INC.

 
	
  

 	
 FOCUS
 TECHNOLOGIES HOLDING COMPANY

 
	
  

 	
 FOCUS
 DIAGNOSTICS, INC.

 
	
  

 	
 HEMOCUE,
 INC.

 

C-12

	
  

 	
  

 
	
  

 	
 KAILASH B.
 SHARMA, M.D., INC.

 
	
  

 	
 LABONE, INC.

 
	
  

 	
 LABONE OF
 OHIO, INC.

 
	
  

 	
 MEDPLUS,
 INC.

 
	
  

 	
 METWEST INC.

 
	
  

 	
 NICHOLS
 INSTITUTE DIAGNOSTICS

 
	
  

 	
 OSBORN GROUP
 INC.

 
	
  

 	
 OCMULGEE
 MEDICAL PATHOLOGY ASSOCIATION, INC.

 
	
  

 	
 O’QUINN
 MEDICAL PATHOLOGY ASSOCIATION, LLC

 
	
  

 	
 PATHOLOGY
 BUILDING PARTNERSHIP

 
	
  

 	
 PCA OF
 DENVER, INC.

 
	
  

 	
 PCA OF
 NASHVILLE, INC.

 
	
  

 	
 PETER G.
 KLACSMANN M.D., INC.

 
	
  

 	
 QUEST
 DIAGNOSTICS HOLDINGS INCORPORATED

 
	
  

 	
 QUEST
 DIAGNOSTICS CLINICAL LABORATORIES, INC.

 
	
  

 	
 QUEST
 DIAGNOSTICS NICHOLS INSTITUTE

 
	
  

 	
 QUEST
 DIAGNOSTICS FINANCE INCORPORATED

 
	
  

 	
 QUEST
 DIAGNOSTICS INVESTMENTS INCORPORATED

 
	
  

 	
 QUEST
 DIAGNOSTICS INCORPORATED (NV)

 
	
  

 	
 QUEST
 DIAGNOSTICS INCORPORATED (MD)

 
	
  

 	
 QUEST
 DIAGNOSTICS LLC (IL)

 
	
  

 	
 QUEST
 DIAGNOSTICS LLC (CT)

 
	
  

 	
 QUEST
 DIAGNOSTICS LLC (MA)

 
	
  

 	
 QUEST
 DIAGNOSTICS INCORPORATED (MI)

 
	
  

 	
 QUEST
 DIAGNOSTICS OF PENNSYLVANIA INC.

 
	
  

 	
 QUEST
 DIAGNOSTICS NICHOLS INSTITUTE, INC.

 
	
  

 	
 REGIONAL
 PATHOLOGY CONSULTANTS, LLC

 
	
  

 	
 ROCKY
 MOUNTAIN PATHOLOGY, LLC

 
	
  

 	
 SHARON G.
 DASPIT, M.D., INC.

 
	
  

 	
 SHOALS
 PATHOLOGY ASSOCIATES, INC.

 
	
  

 	
 SPECIALTY
 LABORATORIES, INC.

 
	
  

 	
 STRIGEN,
 INC.

 
	
  

 	
 TID
 ACQUISITION CORP.

 
	
  

 	
 UNILAB
 CORPORATION

 

C-13

	
  

 	
  

 	
  

 	
  

 
	
  

 	
 QUEST
 DIAGNOSTICS INVESTMENTS INCORPORATED

 
	
  

 	
 QUEST
 DIAGNOSTICS FINANCE INCORPORATED

 
	
  

 	
  

 	
  

 
	
  

 	
 By:

 	
  

 
	
  

 	
  

 	

 

 	
  

 
	
  

 	
  

 	
 Name:

 
	
  

 	
  

 	
 Title:

 

	
  

 	
  

 	
  

 
	
 Attest:

 
	
  

 	
  

 
	
 By:

 	
  

 	
  

 
	
  

 	

 

 	
  

 
	
 Name:
 William J. O’Shaughnessy, Jr.

 
	
 Title:   Assistant
 General Counsel and Corporate Secretary

 

C-14

EXHIBIT D 

FORM OF ADDITIONAL SUBSIDIARY GUARANTEE

                    FOR
VALUE RECEIVED, each of the Subsidiary Guarantors executing this additional
Subsidiary Guarantee (the “Additional Subsidiary Guarantors”), hereby fully and
unconditionally guarantees, jointly and severally, together with the existing
Subsidiary Guarantors (as such term is defined in the Indenture) of the Note,
to the Holder of the Note upon which this additional Subsidiary Guarantee is
endorsed (the “Note”) and to the Trustee on behalf of the Holder, the prompt
payment of the principal of (and premium, if any, on) and interest (including,
in case of default, interest on principal and, to the extent permitted by
applicable law, on overdue interest and including any additional interest required
to be paid according to the terms of the Notes) on the Note, when due (whether
at Stated Maturity, upon Redemption, upon acceleration, upon tender for
repayment at the option of the Company), according to the terms hereof and the
terms of the Indenture (the “Guarantor Obligations”). This Guarantee is a
guarantee of payment and not of collection and is a continuing guarantee and
shall apply to all Guarantor Obligations whenever arising. 

                    Obligations
Unconditional and Absolute. The obligations of the Additional Subsidiary
Guarantors hereunder are absolute and unconditional irrespective of the value,
genuineness, validity, regularity or enforceability of the Indenture or this
Note, to the fullest extent permitted by applicable law, irrespective of any
circumstance whatsoever which might otherwise constitute a legal or equitable
discharge or defense of a surety or guarantor. Each of the Additional
Subsidiary Guarantors agrees that this Guarantee may be enforced by the Holder
of this Note without the necessity at any time of proceeding against the
Company or any other Person (including a co-guarantor) or to pursue any other
remedy or enforce any other right. Each of the Subsidiary Guarantors further
agrees that nothing contained herein shall prevent the Holder of this Note from
suing on this Note or the Indenture or from exercising any other rights
available under this Note and the Indenture, and the exercise of any of the
aforesaid rights and shall not constitute a discharge of any Additional
Subsidiary Guarantor’s obligations hereunder and under the Indenture; it being
the purpose and the intent of each Additional Subsidiary Guarantor that its
obligations under this Note and under the Indenture shall be absolute,
independent and unconditional under any and all circumstances. Neither any
Additional Subsidiary Guarantor’s obligations under this Subsidiary Guarantee
nor any remedy for the enforcement thereof shall be impaired, modified, changed
or released in any manner whatsoever by an impairment, modification, change,
release or limitation of the liability of the Company or by reason of the
bankruptcy or insolvency of the Company. Each Additional Subsidiary Guarantor
waives any and all notice of the creation, renewal, extension or accrual of any
of the Guarantor Obligations or acceptance of this Subsidiary Guarantee. The
Guarantor Obligations, and any of them, shall conclusively be deemed to have
been created, contracted or incurred, or renewed, extended, amended or waived,
in reliance upon this Guarantee. 

                    Subrogation.
Each of the Additional Subsidiary Guarantors shall be subrogated to all rights
of the Holder of the Note against the Company in respect of any amounts paid by
such Additional Subsidiary Guarantor on account of the Note or the Indenture; provided, however,
that such Additional Subsidiary Guarantor shall not be entitled to enforce or
to receive any  

D-1

payments
arising out of, or based upon, such right of subrogation until the principal of
(or premium, if any, on) and interest on all Notes of this series shall have
been indefeasibly paid in full. 

                    Modifications.
Each Subsidiary Guarantor agrees that (a) the time or place of payment of the
Guarantor Obligations may be changed or extended, in whole or in part, to a
time certain or otherwise, and may be renewed or accelerated, in whole or in
part; (b) the Company and any other party liable for payment under the
Indenture or under the Note may be granted indulgences generally; (c) any of the
provisions of this Note or the Indenture may be modified, amended or waived;
and (d) any party (including any Subsidiary Guarantor) liable for the payment
under this Note or under the Indenture may be granted indulgences or be
released; all without notice to or further assent by such Subsidiary Guarantor,
which shall remain bound thereon, notwithstanding any such exchange,
compromise, surrender, extension, renewal, acceleration, modification,
indulgence or release. 

                    Waiver
of Rights. Each of the Additional Subsidiary Guarantors hereby waives to
the fullest extent permitted by law: (a) notice of acceptance of this Guarantee
by the Holder of this Note; (b) presentment and demand for payment or
performance of any of the Guarantor Obligations; (c) protest and notice of
dishonor or default with respect to the Guarantor Obligations; (d) all other
notices to which such Additional Subsidiary Guarantor might otherwise be
entitled. 

                    Reinstatement.
The obligations of the Additional Subsidiary Guarantors under this Note and
under Article Sixteen shall be automatically reinstated if and to the extent
that for any reason any payment by or on behalf of any Person in respect of the
Guarantor Obligations is rescinded or must otherwise be restored by any Holder
of the Notes of this series, whether as a result of any proceedings in
bankruptcy or reorganization or otherwise. 

                    Remedies.
Each of the Additional Subsidiary Guarantors further agrees, to the fullest
extent that it may lawfully do so, that as between each such Additional
Subsidiary Guarantor, on the one hand, and the Holder and the Trustee, on the
other hand, the maturity of the obligations guaranteed hereby may be
accelerated as provided in Article Five of the Indenture for the purposes of
this guarantee, notwithstanding any stay, injunction or other prohibition
extant under any applicable bankruptcy law preventing such acceleration in
respect of the obligations guaranteed hereby. 

                    Rights
of Contribution. The Additional Guarantors, in connection with payments
made hereunder, shall have contribution rights against the other Subsidiary
Guarantors as permitted under applicable law. Such contribution rights shall be
subordinate and subject in right of payment to the obligations of the
Subsidiary Guarantors under this Note and no Additional Subsidiary Guarantor
shall exercise such rights of contribution until all Guarantor Obligations have
been paid in full. 

                    Limitation
of Guaranty. Notwithstanding any provision to the contrary contained herein
or in the Indenture, to the extent the obligations of any Additional Subsidiary
Guarantor shall be adjudicated to be invalid or unenforceable for any reason
(including, without limitation, because of any applicable state or federal law
relating to fraudulent conveyances or transfers) 

D-2

then the
obligations of the Additional Subsidiary Guarantors hereunder shall be limited
to the maximum amount that is permissible under applicable law (whether federal
or state or otherwise and including, without limitation, the Bankruptcy Code). 

                    Release
of Guarantors. Each of the Additional Subsidiary Guarantors hereby
covenants that its Subsidiary Guarantee will not be discharged except by
complete performance of its obligations contained in the Note, this Subsidiary
Guarantee and pursuant to the Indenture;
provided, however,
that if (a) an Additional Subsidiary Guarantor does not guarantee any
Indebtedness of the Company the amount of which, when added together with any
other outstanding Indebtedness of the Company guaranteed by its Subsidiaries
that are not Subsidiary Guarantors, would exceed $50 million in the aggregate,
excluding the Notes of this series, and all outstanding Indebtedness of such
Subsidiary Guarantor would have been permitted to be incurred pursuant to
Section 1011 of the Indenture measured at the time of the release and discharge
as described in this paragraph, (b) the Notes of this series are defeased and
discharged pursuant to Article Fourteen of the Indenture, or (c) all or
substantially all of the assets of such Additional Subsidiary Guarantor or all
of the capital stock of such Additional Subsidiary Guarantor is sold (including
by issuance, merger, consolidation or otherwise) by the Company or any of its
Subsidiaries, then in each case of (a), (b) or (c) above, such Subsidiary
Guarantor or the corporation acquiring such assets (in the event of a sale or
other disposition of all or substantially all of the assets or capital stock of
such Subsidiary Guarantor) shall be automatically and without any further
action on the part of any party to the Indenture, and upon notice to the
Trustee, be fully released and discharged from all its liabilities and
obligations under or in respect of the Indenture and this Subsidiary Guarantee
of the Note, and promptly upon the request of the Company and at the expense of
the Company, the Trustee shall execute such documents and take such other
action as is reasonably requested by the Company to evidence the release and
discharge of such Guarantor from all such liabilities and obligations and
shall, if applicable, certify to the Company that such Additional Subsidiary
Guarantor has no liabilities or obligations resulting from a demand on such
Additional Subsidiary Guarantor’s Guarantee. 

                    Defined
Terms. All terms used in this Note, which are defined in the Indenture and
are not otherwise defined herein, shall have the meanings assigned to them in
the Indenture.

                    Governing
Law. This Subsidiary Guarantee shall be governed by and construed in
accordance with the law of the State of New York. 

                    This
Subsidiary Guarantee shall be governed by and construed in accordance with the
laws of the State of New York, without regard to principles of conflicts of
laws. 

                    Subject
to the next following paragraph, each Additional Subsidiary Guarantor hereby
certifies and warrants that all acts, conditions and things required to be done
and performed and to have happened precedent to the creation and issuance of
this Subsidiary Guarantee and to constitute the same valid obligation of each
Additional Subsidiary Guarantor have been done and performed and have happened
in due compliance with all applicable laws. 

(Remainder of page intentionally left blank.)

D-3

                    This
Subsidiary Guarantee shall not be valid or become obligatory for any purpose
until the certificate of authentication on the Note upon which this Subsidiary
Guarantee is endorsed has been signed by the Trustee under the Indenture
referred to in this Note. 

	
  

 	
  

 	
  

 	
  

 
	
 Dated:

 	
  

 	
  

 	
 [ADDITIONAL
 SUBSIDIARY GUARANTOR(S)]

 
	
  

 	

 

 	
  

 	
  

 

	
  

 	
  

 	
  

 	
  

 	
  

 
	
 Attest:

 	
  

 	
 By:

 	
  

 	
  

 
	
  

 	
  

 	
  

 	

 

 	
  

 
	
  

 	
  

 	
 Name:

 	
  

 
	
  

 	
  

 	
 Title:

 	
  

 
	

 

 	
  

 	
  

 	
  

 
	
 Name:

 	
  

 	
  

 	
  

 	
  

 
	
 Title:

 	
  

 	
  

 	
  

 	
  

 

D-4exv10w26

Exhibit 10.26

AMENDMENT NO. 5 TO CRUDE OIL SUPPLY AGREEMENT

     THIS AMENDMENT NO.5 TO CRUDE OIL SUPPLY AGREEMENT (the “Amendment”), dated as of March 24,
2011 but effective as of March 1, 2011(the “Amendment Effective Date”), is made by and between
CALUMET LUBRICANTS CO., LIMITED PARTNERSHIP, an Indiana limited partnership (“Customer”), and
LEGACY RESOURCES CO., L.P., an Indiana limited partnership (“Supplier”). Each of Customer and
Supplier is sometimes referred to hereinafter individually as a “Party” and they are collectively
referred to as the “Parties.” Capitalized terms used but not defined in this Amendment shall have
the meanings ascribed to such terms in the Agreement (as defined below).

RECITALS

     WHEREAS, Customer owns and operates a refinery in Princeton, Louisiana (the “Refinery”) for
the processing and refining of crude oil into specialty lubricating oils and other refined
products;

     WHEREAS, Supplier is able to obtain certain commodities, including crude oil, from various
supply sources;

     WHEREAS, the Parties entered into that certain Crude Oil Supply Agreement (the “Agreement”)
dated as of April 30, 2008 and as subsequently amended, whereby Customer agreed to purchase from
Supplier, and Supplier agreed to sell and supply to Customer, crude oil on a just in time basis in
order to meet the inventory requirements of the Refinery;

     WHEREAS, pursuant to Section 23 of the Agreement, the Parties desire to amend certain
provisions of the Agreement as of the Amendment Effective Date; and

     WHEREAS, contemporaneously herewith, Customer is delivering to Supplier the Termination Notice
attached hereto as Exhibit A to terminate the Agreement upon the expiration of the Wind Up
Period on May 31, 2011.

AMENDMENT TO AGREEMENT

     NOW, THEREFORE, in consideration of the foregoing recitals and the agreements contained
herein, and for other good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the Parties, intending to be legally bound, do hereby agree to amend the
Agreement as of the Amendment Effective Date as follows:

     1. Defined Term. The definition of the following capitalized term used in the Agreement is
deleted and replaced in its entirety with the following definition:

     “Average Purchase Price” means the sum of (i) the monthly average per barrel price
quoted for the first nearby month for West Texas Intermediate crude oil on the New York
Mercantile Exchange and (ii) $5.15 per barrel, or such other price as may be agreed by the
Parties in accordance with Section 5.

     2. Modification of Effectiveness of Termination. Section 10(c) is deleted and replaced in
its entirety with the following:

1

 

     “(c) Effectiveness of Termination. Termination of this Agreement after a Termination
Notice shall be effective upon the expiration of the Wind Up Period. The Wind Up Period
shall be deemed to have ended on the later of (i) the sixtieth (60th) day
following the date that a Termination Notice is delivered by one Party to the other and (ii)
the last day of the calendar month in which such 60th day occurred if such
60th day is not the last day of a calendar month, in order to effect an orderly
transition to a new crude oil supplier, as crude oil supply arrangements are made on a full
calendar month basis under standard industry practices.”

     3. All other terms and conditions of the Agreement are unchanged and remain in full force and
effect as of the Amendment Effective Date.

[Signature Page Follows]

2

 

     IN WITNESS WHEREOF, the Parties have executed this Amendment as of the date first above
written, but effective as of March 1, 2011.

	 	 	 	 	 
	 	CALUMET LUBRICANTS CO., LIMITED PARTNERSHIP

 	 
	 	By:  	Calumet LP GP, LLC, its general partner
 	 
	 	 	 
	 	By:  	                                                     Calumet Operating, LLC, its sole member
 	 
	 	 	 
	 	By:  	                                                     Calumet Specialty Products Partners, L.P.,
 	 
	 	 	its sole member 	 
	 	 	 
	 	By:  	                                                     Calumet GP, LLC, its general partner
 	 
	 	 	 
	 	By:  	                                                     /s/ R. Patrick Murray, II
 	 
	 	 	Name:  	R. Patrick Murray, II 	 
	 	 	Title:  	Vice President & CFO 	 
	 
	 	LEGACY RESOURCES CO., L.P.

 	 
	 	By:  	Legacy Acquisitions, Inc., its general    partner
 	 
	 	 	 
	 	By:  	                                                     /s/ Mark F. Smith
 	 
	 	 	Name:  	Mark F. Smith 	 
	 	 	Title:  	President 	 
	 

 

 

EXHIBIT A

TERMINATION NOTICE

     Pursuant to Section 10 of that certain Crude Oil Supply Agreement, dated as of April 30, 2008
and as subsequently amended through March 24, 2011 (the “Agreement”), by and between CALUMET
LUBRICANTS CO., LIMITED PARTNERSHIP, an Indiana limited partnership (“Customer”), and LEGACY
RESOURCES CO., L.P., an Indiana limited partnership (“Supplier”), effective March 24, 2011 (the
“Notice Date”), Customer hereby delivers to Supplier this Termination Notice to terminate the
Agreement upon the expiration of the Wind Up Period on May 31, 2011, in accordance with Section
10(c) of the Agreement, and Supplier hereby acknowledges the receipt of this Termination Notice on
the Notice Date. Capitalized terms used but not defined in this Termination Notice shall have the
meanings ascribed to such terms in the Agreement.

[Signature Page Follows]

 

 

	 	 	 	 	 
	 	CALUMET LUBRICANTS CO., LIMITED
PARTNERSHIP

 	 
	 	By:  	Calumet LP GP, LLC, its general
partner

 	 
	 	By:  	Calumet Operating, LLC, its sole
member

 	 
	 	By:  	Calumet Specialty Products
Partners, L.P., its sole member

 	 
	 	By:  	Calumet GP, LLC, its general
partner

 	 
	 	By:  	/s/ R. Patrick Murray, II
 	 
	 	 	Name:  	R. Patrick Murray, II 	 
	 	 	Title:  	Vice President & CFO 	 
	 

	 	 	 	 	 
	AGREED AND ACKNOWLEDGED:

This 24th day of March, 2011.

LEGACY RESOURCES CO., L.P.

 	 	 
	By:  	Legacy Acquisitions, Inc.,
 	 	 
	 	its general partner 	 	 
	 	 	 	 
	 
	 	 	 
	By:  	/s/ Mark F. Smith
 	 	 
	 	Name:  	Mark F. Smith 	 	 
	 	Title:  	President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00186-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00186-of-00352.parquet"}]]